National Cancer Plan Call for Evidence

Andrew Gwynne Excerpts

Tuesday 4th February 2025 Written Statements

[The Parliamentary Under-Secretary of State for Health and Social Care (Andrew Gwynne)]

With today being World Cancer Day, I want to be clear about this Government’s commitment to transforming cancer care and ensuring that fewer people die from this devastating disease by launching our call for evidence for a new national cancer plan.

One in two people will develop cancer in their lifetime and we are currently diagnosing and treating near record numbers of patients, with over 350,000—357,378—people receiving their first treatment over the last 12 months. This is expected to increase significantly as the population ages, with Cancer Research UK forecasting half a million cancer cases each year by 2040. The Tobacco and Vapes Bill will put us on track to a smoke-free UK, helping to reduce around 80,000 preventable deaths and reduce the burden on the NHS and on the taxpayer. While around 40% of cancers are caused by avoidable factors such as smoking, we know that much of the rise in cancer cases will be caused by ageing and is unavoidable.

We know the issues that are key to improving cancer survival. We know we need patients to be seen faster and cancers to be diagnosed earlier to secure better patient outcomes. We know that reducing the time it takes to be diagnosed and treated can make a crucial difference to a patient’s outcome. I want every patient to get excellent care and treatment, and to achieve that, we need an effective and sustainable health and social care sector.

The independent review of the NHS by Lord Darzi set out the scale of the challenges we face in fixing the NHS, and the need to improve cancer waiting time performance and cancer survival. At the same time, he pointed to the NHS’s success in delivering targeted lung health checks. That is transforming the early diagnosis of lung cancer in disadvantaged communities—something that he described as a sign of hope.

In response to the Darzi report, we have launched an extensive programme of engagement to develop a 10-year health plan to reform the NHS. We need the 10-year health plan to set out how we can build a health system fit for the future. It will set out the framework of reforms we need to ensure better outcomes across the NHS and to meet significant challenges like cancer. Furthermore, our elective reform plan sets out how we will return to the 18-week constitutional standard and put patient experience front and centre.

However, we know that the increasing number of cancer cases and the complexity of cancer care mean that we need a specific approach to cancer that aligns with our wider vision of how we want to reform the NHS. As a result, I am delighted to inform the House that we will publish a national cancer plan later this year, following publication of the 10-year health plan. I am determined to reduce the number of lives lost to cancer, and to ensure that many more people go on to lead a full life after their cancer treatment. The national cancer plan is the first step to preventing, diagnosing, and treating cancer more effectively. To achieve this goal, the plan will look at the full range of factors and tools that will allow us to transform outcomes for cancer patients and improve their experiences of treatment and care.

We cannot do this alone, and that is why we are launching a call for evidence from patients, doctors, nurses, scientists, our key partners, and other members of the public on what should be included in the plan.

Following a period of planning and engagement with our partners across the cancer community, we will aim to publish the national cancer plan in the second half of 2025.

I am pleased to inform the House that we will also be relaunching the children and young people’s cancer taskforce to identify ways to improve outcomes and patient experience for children and young people with cancer. Dame Caroline Dinenage and Professor Darren Hargrave have been appointed as its co-chairs, alongside Dr Sharna Shanmugavadivel as vice-chair. I will update the House on progress in due course.

[HCWS415]

Accessibility of Radiotherapy

Andrew Gwynne Excerpts

Tuesday 4th February 2025 Westminster Hall

[Clive Jones (Wokingham) (LD)]

It is a pleasure to serve under your chairship, Sir John. I thank my hon. Friend the Member for Westmorland and Lonsdale (Tim Farron) for securing this debate and for his dedication on this issue. I declare an interest as a governor of the Royal Berkshire hospital. I also have a family member who has shares in a medical company.

Radiotherapy access suffers from geographical constraints, and this issue cannot be solved until the significant workforce challenge is addressed alongside it. The Royal College of Radiologists states that in England the NHS faces a 30% shortfall in radiologists. That figure is projected to rise to 40% by 2028, yet more than a fifth of NHS trusts have implemented recruitment freezes. Shortfalls in recruitment mean that consultants, faced with burnout and impossible workloads, retire earlier. That is made especially clear as the average age of retirement is just 54.

The Royal College of Radiologists highlights the absurd situation whereby newly trained consultants may struggle to find jobs, forcing invaluable radiologists and oncologists to go for locum jobs, move abroad or leave the healthcare sector altogether at a time when their skills are best placed in our NHS to fix our cancer care crisis—a crisis in which not a single integrated care board is currently meeting its cancer waiting time standards.

The impact of the recruitment freezes on patients is tangible and is not limited to radiotherapy. Some 80% of patient pathways in the NHS are reliant on radiology. Delays in scan reporting result in delayed treatment. Delayed treatment results in worse outcomes. Worse outcomes may be the deciding factor in whether someone fails to recover.

How will the Government ensure that when my Wokingham constituents visit the Royal Berkshire hospital, the oncology and screening departments are fully staffed? Can the Minister explain his understanding of the recruitment freezes that are taking place across NHS trusts? I am aware that the Minister has a very, very busy diary: he told me so earlier today in the main Chamber.

[The Parliamentary Under-Secretary of State for Health and Social Care (Andrew Gwynne)]

I suspect that my diary will be a little busier with the two requests from the hon. Member for Westmorland and Lonsdale (Tim Farron).

[Clive Jones]

The Minister’s diary will be a little busy, but I am sure it can cope. I ask him to meet me and representatives of the Royal College of Radiologists to discuss the Government’s plan for workforce reform.

--- Later in debate ---

[The Parliamentary Under-Secretary of State for Health and Social Care (Andrew Gwynne)]

It is a pleasure to serve under your chairmanship, Sir John. I thank the hon. Member for Westmorland and Lonsdale (Tim Farron) for bringing this important debate to Parliament on World Cancer Day, and other Members for their contributions on this really important topic. I am happy to meet the hon. Member and his colleagues from the all-party parliamentary group on radiotherapy to discuss these issues further. I suspect that my diary is going to get busier, but I am more than happy to meet the hon. Member for Wokingham (Clive Jones) as well, to ensure that we get this aspect of the national cancer plan absolutely right.

To answer one of the questions put by the shadow Minister, the hon. Member for Sleaford and North Hykeham (Dr Johnson), the national cancer plan will include radiotherapy—it would be odd if it did not, given the importance of radiotherapy—and I will work with Radiotherapy UK and others with an interest in this area. That is partly why we have launched our call for evidence today: to get the views and opinions of as many people and organisations as possible, so that we get the plan right. It has to be fit not just for 2025, but for 2035 and the years in between, so there is a lot of work to be done.

We know that cancer patients are waiting too long for treatment. That is why we are taking immediate action to kick-start the recovery of the NHS with a commitment to cut waiting times that will benefit all, including those with cancer. In our 10-year plan for the NHS, we committed to return our national health service to constitutional standards, including on cancer.

By investing in our workforce, a point made by several hon. Members, and allocating £70 million for new radiotherapy machines, we will reduce cancer waiting times and give more patients access to state-of-the-art treatments. Fixing the NHS also requires reform. This year, we will publish our 10-year health plan to help build a health service fit for the future and, as I have already mentioned, we are today announcing the launch of a call for evidence for a dedicated national cancer plan, another step towards unleashing our country’s potential as a world leader in saving lives from this deadly disease. I encourage everyone to have their say by responding to the national cancer plan call for evidence.

I assure hon. Members that the priority of this Government is to ensure that radiotherapy is available quickly to those who need it. Radiotherapy is a crucial treatment for many cancer patients, as it can shrink tumours very effectively. Although the vast majority of the population are located within reasonable distance of where they would go for treatment, I am very aware that that is not always the case, particularly in rural communities.

I can give a family example. My dad, who sadly died two years ago from a very rare and aggressive form of rectal cancer, benefited from superb treatment at the Christie in Manchester, which is our local cancer hospital. He had chemotherapy, immunotherapy and radiotherapy. The radiotherapy shrank his tumours, and that almost certainly gave him an extra two years of quality life with his family, including his great-grandson. I will forever be grateful that he received that.

One day, though, we took him to the Christie and he got chatting to somebody who was also receiving radiotherapy. This is pertinent to the hon. Member for North Shropshire (Helen Morgan), who leads on these matters for the Liberal Democrats, because this person was from Shropshire. My dad is Salopian born—he was born in Shrewsbury and brought up in High Ercall, before being dragged to Manchester in the 1950s when my grandad got a job as the chief accountant at Manchester education committee—and they got talking. “You’re really from Shropshire and you’re coming to Manchester for radiotherapy?” It was the nearest place that had that treatment available at that time. It really hit me then how sporadic these things are, and how some people have to travel unacceptably long distances. We need to make sure that in our national cancer plan, we look at the deserts and the accessibility issues.

[Tim Farron]

I would not be doing my job at all well if I did not pursue the Minister on this point. Earlier, he very kindly talked about meeting the all-party group to talk about the national picture, and I want to press him on our local bid to tackle the problem he has just spoken about. Will he meet me and local oncologists to talk about how we can deliver a radiotherapy satellite centre in Kendal?

[Andrew Gwynne]

I was just coming to that—the hon. Gentleman has obviously started to read my notes from a distance. I am aware that he met representatives of the previous Government to discuss the possibility of a satellite unit in his local area. The situation is the same now as it was then: it is the responsibility of the integrated care board, but if the hon. Gentleman thinks it would be helpful for us to have a meeting and see if we can push that case, my door is open. I absolutely recognise that people in that part of Cumbria would prefer to have those services closer to where they live. If we can impress that on his local ICB, let us see if we can make progress.

The Government aim to ensure that each treatment centre is accessible to the highest possible number of patients, as well as easily reached by the staff who work there. That is another consideration—it is not just the patients who have to physically get to these units, but the staff. We recognise that for those in rural communities, machinery may not be available at their local hospital, meaning that the only option is travel to specialist centres to receive the best possible care. Radiotherapy service provision is agreed by local systems, and each patient’s care needs and treatment location are decided on a case-by-case basis by their clinicians. We are giving local systems greater flexibility and control, as they are best placed to understand and meet the needs of their communities, but to drive the national cancer plan forward, we have to tackle this postcode lottery and the deserts head-on.

Accessibility is also about making sure that we have the right workforce available to deliver the treatment in the right places and at the right time. That is why the number of training places has increased, and it is why we are improving the quality of education for assistant practitioners, diagnostics and therapeutic radiographers. NHS England is also working to improve the retention of radiographers and radiologists through initiatives such as increasing investment in career development. By ensuring our workforce feels supported, we put ourselves in a better position to deliver the care that people need.

Turning to investment in machines, I agree with the hon. Member for Westmorland and Lonsdale that we should be ambitious in our plans to ensure that patients are treated as quickly as possible. Lord Darzi’s report highlighted the scale of the challenge we face: under the previous Government, waiting times for treatment increased, and more than 30% of patients waited longer than 31 days for radical radiotherapy.

In response to Lord Darzi’s findings, we have taken urgent action to get the NHS back on its feet. At the recent Budget, my right hon. Friend the Chancellor supported our commitment to end the backlogs by announcing £70 million of investment in new radiotherapy machines in 2025-26. Replacing older radiotherapy machines with newer, more efficient and more technically advanced ones will ensure that patients can be seen more quickly. By doing so, we will improve access and speed up cancer treatment. Making more advanced machines available means that patients will have fewer trips to receive their treatment.

Hon. Members may be aware that NHS England has now allocated funding to trusts across the country to purchase the new radiotherapy machines with the £70 million investment. NHS England invited trusts to express interest in receiving funding to purchase a new machine. Allocation criteria focused on the age of the machine being replaced, the proportion of older machines in use in the trust and the trust’s performance on radiotherapy. We expect to fund at least 27 new machines, which should be available to treat patients by spring 2026.

Those steps will ensure that we can improve cancer waiting times as soon as possible, helping us to put an end to the last Government’s neglect and underinvestment. I reassure the hon. Member for Westmorland and Lonsdale, and other hon. Members, that we will continue to make the case for additional funding, so that we can continue to upgrade machines and push the advances of the latest technological developments, for the benefit of patients with cancer.

I turn to the national cancer plan. Beyond immediate actions, we know that bold reform is required to rise to the growing challenge that cancers of all types represent. Lord Darzi found that cancer survival in this country is worse than in comparable countries, and that improvement slowed greatly during the 2010s. To help us to develop more targeted actions, my right hon. Friend the Secretary of State has announced the development of a national cancer plan, which was the subject of the statement I gave in the House just a few hours ago. The overarching aim of the plan is to reduce the number of lives lost to cancer. It will detail how we will improve outcomes for cancer patients, ensuring that patients have access to the most effective treatments and technology, including radiotherapy.

Today, we launched our national cancer plan call for evidence. We welcome views from all hon. and right hon. Members, as well as from clinicians, patients and their families—it is critical that we get the views of people who have lived experience of accessing cancer care—charities, researchers, members of the public and, of course, the excellent all-party parliamentary groups that champion cancer treatment and outcomes in this House.

In closing, I thank the hon. Member for Westmorland and Lonsdale for bringing this crucial matter to the House. I thank hon. Members, whose contributions have, in the spirit of this year’s World Cancer Day, put places and people at the centre of care. I am pleased to assure hon. Members that we are undertaking both immediate actions and bold reforms to improve access to radiotherapy. There is a lot more that we need to do, and we will do it in partnership. This work is part of our effort to rebuild the NHS and deliver world-class cancer services for everybody—something that will always be a top priority for this Government and that is personal for me—so let’s get on and achieve it.

National Cancer Plan

Andrew Gwynne Excerpts

Tuesday 4th February 2025 Commons Chamber

[The Parliamentary Under-Secretary of State for Health and Social Care (Andrew Gwynne)]

With permission, I wish to make a statement on the national cancer plan. Today is World Cancer Day. Almost everyone in our country has been affected by cancer, either themselves or through a friend or relative. Having lost both my parents to cancer, I am so grateful to the Prime Minister for giving me this job. He has given me the chance of a lifetime to do my parents proud by creating the kind of compassionate and humane healthcare that all our constituents deserve.

I am also pleased to be led by a survivor of kidney cancer, my right hon. Friend the Secretary of State for Health and Social Care. His experience as a patient will be invaluable to us in the months ahead. I pay tribute to the amazing cancer charities who do fantastic work to help people live with cancer, support bereaved families and drive vital research in this area—Macmillan, Cancer Research UK, Cancer52 and Marie Curie to name just a few.

Lord Darzi’s investigation set out the scale of the challenges that we face in fixing the NHS, and how desperately we need to improve cancer diagnosis rates, waits and outcomes. He found that

“the UK has substantially higher rates than our European neighbours, Nordic countries, and countries that predominantly speak English”.

There were close to 100,000 more cases of cancer in 2019 than in 2001. While survival rates at one year, five years and 10 years have all improved, the rate of improvement slowed substantially during the 2010s.

Lord Darzi also noted important inequalities in the provision of cancer care; people in the most underserved areas are more likely to present as an emergency. As Cancer Research UK pointed out in its submission to the investigation, the 62-day target for referral to treatment has not been met for almost 10 years. Last May, performance was at just under 66%, with more than 30% of patients waiting longer than 31 days to start radical radiotherapy.

For all those reasons and more, we do not have a second to waste. That is why the Prime Minister kicked off this year with our elective reform plan, setting out how we will cut the longest waiting times from 18 months to 18 weeks. From March next year, around 100,000 more people every year will be told if they have cancer or not within 28 days, and around 17,000 more people will begin treatment within two months of diagnosis. That is why this year, we will spend £70 million on replacing older radiotherapy machines with newer, more efficient models. That is why in the King’s Speech we put forward an improved Tobacco and Vapes Bill, helping to reduce around 80,000 preventable deaths and putting us on track to a smoke-free UK.

While around 40% of cancers are caused by avoidable factors such as smoking, the backdrop is one of an ageing society. Cancer Research UK has forecast half a million cancer cases each year by 2040. We are preparing for the future now, with our 10-year health plan for the NHS. The plan will set out the framework of reforms that we need to ensure better outcomes and to meet the growing challenges that we face in the fight against this dreadful disease. The plan will play to Britain’s strengths as a global leader in the development of advanced therapies, using our strong academic and life sciences industry.

We should remember that the NHS was the first health service in Europe to commission CAR-T cellular therapy for blood cancer patients. On this World Cancer Day, I can announce that we will build on that legacy by investing in a cutting-edge, world-leading trial to transform breast cancer care through artificial intelligence. Nearly 700,000 women will take part in this trial, testing how cutting-edge AI tools can be used to catch breast cancer cases earlier. Thirty testing sites across the country will be enhanced with the latest digital AI technologies, ready to invite women already booked in for routine screenings on the NHS to take part.

The technology will assist radiologists by screening patients to identify changes in breast tissue that show possible signs of cancer, with referral for further investigations if required. If the trial is successful, it has immense potential to free up hundreds of radiologists and other specialists across the country to see more patients, tackle rising cancer rates and save more lives. It is just one example of how British scientists are at the forefront of transforming cancer care, and of the promising potential of cutting-edge innovations to tackle one of the UK’s biggest killers.

This Government know that unless we do things differently, our NHS will remain in the dire state in which we inherited it. That means proper reform, from doing away with burdensome process that holds back frontline staff to handing more power to local leaders so that they can deliver for the communities they know best. It also means embracing new technologies, including AI, to transform the way we deliver care and to improve patient outcomes. Today’s trial is yet more evidence of this Government taking action to bring in the reform that is desperately needed. As the Prime Minister set out last month, our plan for change will put the UK on the front foot, unleashing AI to drive up health services and shift the NHS from analogue to digital, as part of our 10-year plan.

Our 10-year plan will ensure that the NHS is there for our grandchildren and future generations, but we believe that the increasing number of cancer cases and the complexity of cancer care mean that we need a specific approach to cancer. We are determined both to bring down the number of lives cut short by cancer and to ensure that many more people go on to lead a full life after their treatment. That is why I am today announcing a call for evidence for our new national cancer plan that we will publish following the 10-year plan in the second half of this year. We will look at the full range of factors and tools that will allow us to transform outcomes for cancer patients while improving their experiences of treatment and care. We will make the United Kingdom a world leader in cancer survival by fighting the disease on all fronts—through better research, diagnosis, screening, treatment and prevention. However, we cannot do this alone, and that is why we are launching this call for evidence from patients, doctors, nurses, scientists, our key partners and other members of the public on what should be included.

To support that work, we will relaunch the children and young people’s cancer taskforce, co-chaired by the hon. Member for Gosport (Dame Caroline Dinenage) and Professor Darren Hargrave, with Dr Sharna Shanmugavadivel as vice-chair. I’ve put my teeth in—apologies if I pronounced that wrong. The taskforce will bring together the country’s top experts to set out plans to improve treatment, detection and research for cancer in children, which will feed into the plan. At every stage, we will ensure that patient voices are heard. I look forward to updating the House on the progress of the plan, the taskforce and the trial throughout the year.

Many of us on the Government Benches remember with pride the previous Labour Government’s record in the fight against cancer. We introduced landmark legislation to ban smoking in public places, protecting a generation of children from the harms of second-hand smoke, while putting record sums into smoking cessation programmes. At the dawn of the millennium, we launched a national cancer plan, which led to faster cancer diagnosis and treatment times, increased funding for cancer services, equipped the national health service with radiotherapy machines—many of which are still there—and expanded cancer research funding, so that a new generation of scientists could answer the call. What did that plan lead to? Survival rates went up. The number of patients diagnosed and treated on time went up. The number of lives lived well after cancer went up. That was our record in government, and we will do it again. I commend this statement to the House.

[Madam Deputy Speaker (Caroline Nokes)]

I call the shadow Minister.

[Dr Caroline Johnson (Sleaford and North Hykeham) (Con)]

I thank the Minister for advance sight of his statement, and I thank all the NHS workers, charities, scientists and others working to help those with cancer.

We can all agree that tackling cancer should be a top priority for the NHS. From diagnosing people quickly to starting treatment quickly and using the latest technology and drugs, we all want to see improvements. The recent trends in cancer survival rates are positive. The one-year survival rate for cancer increased by 5.9% between 2010 and 2020, and the five-year survival rate increased by 4.3% in the same period. Despite those improvements, we are not yet where we want to be, and we will be up front about that.

In government, we took action to catch cancer sooner and boost survival rates, with initiatives such as lung cancer screening and prostate cancer trials, and we welcome that Labour is continuing with that mission. We will work constructively with the Government on that, as we all want to achieve the same positive outcomes. However, the statement as a whole is rather disappointing. The Minister has told us that this is a cancer plan, but it is not; it is a statement that there is to be one. The Government saying that they want cancer survival rates to increase and that they are going to have a plan does not make it so—we need the plan itself.

The announcement of the AI trial in breast cancer is a welcome approach. Artificial intelligence has the capacity to revolutionise the way we diagnose disease, and I am delighted that the Government wish to explore those opportunities. We also very much welcome the relaunch of the children and young people’s cancer taskforce, and are pleased it will be able to continue its valuable work under the co-chairmanship of my hon. Friend the Member for Gosport (Dame Caroline Dinenage) and Professor Darren Hargrave. It is just a shame that the Labour Government wasted seven months by suspending the Conservative taskforce, only to reinstate it now.

I note the Minister’s comments about waiting times to start treatment, and we agree that these must improve. I am sure it will not have escaped his notice that NHS Wales, which has been under a Labour Administration for 25 years, has a poorer performance, and I am certain he would not want party politics to affect such an issue. Can he tell the House what conversations he is having with his Welsh counterparts to improve cancer care there?

I am also concerned that last month, the Government appeared to quietly abandon the target of ensuring that patients receive treatment a maximum of 62 days from an urgent referral of suspected cancer, despite the Health Secretary having said before the election that a Labour Government would meet that target within the first term. Will the Minister clarify his commitment to the 62-day target?

More scanners are, of course, welcome, but what are the Government doing to ensure that there are enough trained professionals to interpret the results of the scans effectively?

With charities such as Macmillan and Marie Curie being hit with devastating increases in national insurance contributions, what help will be provided so that they do not have to cut back the vital support and guidance services they provide to cancer patients?

Anyone who has faced cancer will know that time is of the essence. The second half of the year—if it is not until December—could be quite a long time from now. Will the Minister therefore be more clear about when he intends to publish the plan? May I recommend using the evidence collected in our 2022 call for evidence, as well as the policies of the interim major conditions strategy, published in 2023, to speed up the plan? The quicker the Government act, the more lives they will be able to save.

[Andrew Gwynne]

I start by genuinely thanking the shadow Minister for the co-operation she has pledged as we seek to improve the outcomes for people with cancer. This is not a party political issue. We all want people to be diagnosed more quickly and to be put on the effective treatment pathways as quickly as possible, and we all want people to have better outcomes. I would just remind her, however, that while progress was made over the past decade, as I referred to in the statement, Lord Darzi clearly set out that the rate of progress was much slower than in comparator countries, and that we could and should have been on a much better trajectory.

That is why we are committed to a new national cancer plan—something for which the sector has been calling for some time. We are going to consult on that plan. I hope the shadow Minister is not suggesting that we should just pull a plan out of thin air without any consultation with the sector, patients or anybody with any interest in cancer.

Of course, things have changed over recent years. New technology has advanced and scientific progress is advancing, although there are still some areas where, stubbornly, there is not enough research. We need to build up the case for research and get the funding in; I think especially of brain tumours, where, quite frankly, things have not progressed at all. We need to ensure that in the 10-year cancer plan, we really drive forward in some of those areas, using the latest technology and scientific advances.

The shadow Minister asked about targets. I just say to her that we have actually strengthened targets, rather than setting new ones for cancer. Currently, the NHS is on track to deliver against its cancer targets for this year. Yes, we should be ambitious where we can, and that is exactly what this Labour Government are going to do.

[Dame Siobhain McDonagh (Mitcham and Morden) (Lab)]

I am delighted to announce to the House that we will be opening a drug trial for glioblastoma brain tumours in May, in memory of my late sister, Margaret. [Hon. Members: “Hear, hear.”] But for how long will progress on this depend on people baking cakes, running marathons and organising dinners? When will the NHS and the National Institute for Health and Care Research get their act together and do something for the 3,200 people who will be diagnosed with this dreadful illness this year?

[Andrew Gwynne]

I am very grateful to my hon. Friend for her question. Those of us who knew Margaret miss her very much; she was such a towering figure in the Labour party for so many years, and we on the Labour Benches have a lot to thank her—and, indeed, my hon. Friend—for.

My hon. Friend is absolutely right on research. This is one area where, quite frankly, we have not done well enough. We have not made any progress. I know she will continue to champion more research. With our new national cancer plan, I hope that she will be pushing on an open door, because this is one area we absolutely have to do much better in.

[Madam Deputy Speaker (Caroline Nokes)]

I call the Liberal Democrat spokesperson.

[Jess Brown-Fuller (Chichester) (LD)]

Nearly every family has a cancer story, whether it is a personal fight or that of a loved one. A 10-year plan from the Government is a welcome step, as the previous Government broke their promise to implement a 10-year cancer strategy that would have made a real difference to patients. We on the Liberal Democrat Benches are very proud that our cancer campaigner, my hon. Friend the Member for Wokingham (Clive Jones), secured from the Government a commitment to introduce such a plan.

Testing for cancer, diagnosing and starting treatment quickly reduces stress and anxiety. Also, if the cancer is caught early, it is more likely to be treated successfully. Yet the target of 85% of people receiving their diagnosis and starting treatment within 62 days of an urgent referral has not been met since December 2015. In my constituency, one third of cases fall short of that target and 1,000 families lose a loved one every year to this cruel disease.

Lord Darzi’s review laid out very clearly that the UK has appreciably higher cancer mortality rates than other countries and that more than 30% of patients are waiting longer than 31 days for radical radiotherapy. A quarter of England’s 280 radiotherapy machines are now operating beyond their recommended 10-year lifespan, and in some areas, such as West Sussex, there is no access to radiotherapy at all. That is why we welcomed the £70 million investment announced in October to start to replace the older radiotherapy machines.

Will the Minister confirm whether there will be further rounds of funding to keep pace with available radiotherapy technology? Will he look to support those at the mercy of a postcode lottery by ensuring that radiotherapy is available in all areas? What is the expected timeline for reversing the damage done by the previous Government, and when can all patients expect to start their treatment within the 62-day urgent referral target?

[Andrew Gwynne]

One reason we think a national cancer plan is so important is precisely to get the investment in the areas we need so that we can tackle those health inequalities. There are very real inequalities when it comes to the diagnosis of cancer and, more importantly, the treatment and therefore the outcomes. I am really keen that we focus on that in the plan, to ensure that all parts of the country achieve the best outcomes for people who have been diagnosed with cancer.

Part of the plan is the roll-out of community diagnostic centres so that we can get diagnosis much earlier. That then puts greater pressure on getting people through the front door for treatment, so that is why, as part of the recovery plan that the Prime Minister and the Health Secretary announced, we are seeking to get more people treated more quickly on those treatment pathways. Hopefully, that will get the desired outcomes we want. It is a commitment that we will seek to restore the national health service to its constitutional standards. That is a priority of this Government.

On radiotherapy machines, the £70 million investment will fund about 25 or so machines. The criteria for evaluating bids are the age of the machine, the proportion of machines aged over seven years, and the performance against the 31-day standard for radiotherapy, with poorer performers prioritised. On future rounds of funding, the cancer plan will feed into spending reviews and future Budgets. It is our priority to ensure that we reach the cancer targets, so hopefully we can make the case to the Treasury for future investment in further years.

[Derek Twigg (Widnes and Halewood) (Lab)]

As someone who lost his wife to cancer, I know the dire circumstances that a cancer diagnosis can bring. It is right that cancer plans should focus on the best outcomes: improving the amount of time that people live for, or having a cure. I would like to raise with the Minister the specific issue of pain relief management. As part of the plan, will he ensure that there is an investigation into how pain relief management can be improved for cancer patients, and that it is given not just during the week but at weekends too?

[Andrew Gwynne]

Absolutely. My hon. Friend raises a really important point about how people receive pain relief and how that is managed. There are some really good examples out there of how it is done really well and, shockingly, there are some that are less good. We want to learn from the best. As my right hon. Friend the Secretary of State says, it is about taking the best of the NHS to the rest of the NHS. Absolutely, that should form part of the plan.

[Mr James Cleverly (Braintree) (Con)]

Like many people in this House, I have seen up close and personal the devastating impact that a cancer diagnosis can have on people and families. I have also seen the difference between an early diagnosis and a later diagnosis, which is why I very much welcome the use of AI in early diagnosis. One positive by-product of having a long-standing national health service is that we have in the UK a very large database of historical tissue samples. Will the Minister consider using AI to do a retrospective analysis of those historical tissue samples to try to spot patterns that could inform future speedy diagnosis across a whole range of cancers?

[Andrew Gwynne]

I thank the right hon. Gentleman for that suggestion and will ask my officials to look into it. I am very keen that we maximise the latest advances in technology, genomics, life sciences and research to ensure that we identify people who are at risk of cancer, preferably before they develop cancer, so that we can get them on appropriate treatments where necessary and they avoid the pain and misery that cancer can bring.

[Mrs Sharon Hodgson (Washington and Gateshead South) (Lab)]

On this World Cancer Day, will my hon. Friend the public health Minister tell me what efforts he is making to raise awareness of the signs and symptoms of ovarian cancer, such as a bloated tummy, lack of appetite or feeling full, tummy pain or needing to pee more often, in order to increase lifesaving early diagnosis?

[Andrew Gwynne]

I am very grateful to my hon. Friend for all the work that she has done on ovarian cancer since becoming an MP. She knows—the rest of the House might not—that I lost my mum to ovarian cancer. I was 19 when my mum died and she was only 50—my age today. She had a late diagnosis. They basically opened her up to perform a hysterectomy and the cancer had spread all the way through her body. They sewed her back up and she died at the end of a hospital ward two days later in pain and agony. Having awareness of those symptoms is so important. My mum was fobbed off by her GP, because she worked in a shop and lifted boxes. She had a bad back and was bloated and so on. The GP said it was down to her work, rather than erring on the side of caution and getting her checked out. We must ensure that women today are heard by GPs and, more importantly, that we err on the side of caution and get people on to treatment.

[Dame Caroline Dinenage (Gosport) (Con)]

The Minister is absolutely right to focus on this. I warmly welcome the reinstatement of the children and young people’s cancer taskforce. I take this opportunity to pay tribute to my constituent Charlotte Fairall, who was pivotal in the work to bring the taskforce together in the first place. Charlotte’s daughter Sophie died of rhabdomyosarcoma when she was just 10 years old. I know the Minister met Charlotte to discuss this issue. Unfortunately, Sophie is not alone—around 500 children and young people die of cancer every year in the UK. It is the biggest cause of death by illness of children under the age of 14. Sophie had a wish list of things that she wanted to achieve before she died, including cooking with Gordon Ramsay and wearing high-heeled shoes, but she also wanted to meaningfully change the way we detect, treat and care for children with cancer. Does the Minister agree that the taskforce is a great step in that direction?

[Andrew Gwynne]

It absolutely is, and I thank the hon. Lady for agreeing to co-chair the re-formed taskforce. I know that she cares passionately about this issue, and it was lovely to meet Charlotte some time before Christmas.

Cancer is terrible, and cancer affecting children even more so. As the hon. Lady knows, we paused the taskforce because the general election got in the way. We wanted to carry out a real-time stocktake to establish whether we needed all these different taskforces, but, along with Charlotte, she convinced me, and convinced the Secretary of State, that the work of this taskforce will be crucial to informing our national cancer plan, and I wish her all the best in securing the outcomes that both she and I want to see.

[Peter Prinsley (Bury St Edmunds and Stowmarket) (Lab)]

Does the Minister agree that the move from analogue to digital will be key to cancer research, especially in the field of rare cancers such as the brain tumours that we have been hearing about?

[Andrew Gwynne]

I absolutely do. That shift to analogue to digital, and the use of the latest advantages in technology, science and research, will push the boundaries of what is possible when it comes to diagnosing and treating some of the rarer cancers, on which we have made virtually zero progress in recent years. I think that, with the right direction, the right commitment and the right drive, we can really start to make inroads in this area.

[Tim Farron (Westmorland and Lonsdale) (LD)]

May I invite the Minister, and indeed everyone here, to join us in Room M after these exchanges, when Radiotherapy UK will have a drop-in session with—most important—our patron Bryan Robson, England’s Captain Fantastic? I thank him for mentioning radiotherapy in his statement, which is crucial step forward, but may I suggest that he and the Government need to show exponentially greater ambition to get this right? The UK spends 5% of its cancer budget on radiotherapy, while the OECD average is 9%, which is why the UK is at the bottom of the survival league for so many cancers. Will the Minister commit himself to putting that right?

[Andrew Gwynne]

I am not sure that I will be able to attend the hon. Gentleman’s meeting, but I will certainly be in Westminster Hall for his debate later this afternoon. I understand exactly the concerns of people who are championing the need for increased access to radiotherapy treatments. My dad benefited from radiotherapy at the Christie, which probably gave him an extra couple of years of life with his family—I will be forever grateful for that. I get it; I understand it; we need to make the case.

[Imran Hussain (Bradford East) (Ind)]

I thank the Minister for his welcome statement, and join him in thanking all the organisations that do the vital work of helping and supporting those with cancer and their families. He is right to talk about health inequalities, which, as he will know, continue to worsen in constituencies such as mine, where, on average, people live 10 years less than others in more affluent areas; and last year more than 13,000 were waiting for diagnostic tests. Will he join me in commending the work of Eccleshill community diagnostic centre in Bradford— essential, and the first of its kind—which is speeding up the detection of life-threatening conditions such as cancer, and will he assure me that, as part of his national action plan, more support will be given to places such as Bradford and the Eccleshill community diagnostic centre, so that no one is left behind when it comes to their treatment?

[Andrew Gwynne]

As my hon. Friend says, tackling health inequalities is a key priority for this Government, in relation to our health mission but also more generally, when it comes to some of the big conditions such as cancer. In areas such as his and mine, the prevalence of cancer is greater, because of the industrial legacy, and also because the prevalence of smoking is still much higher than the national average. I commend the work of his local diagnostics team, and we need much more of that best practice to be spread across the areas that need it the most.

[Martin Vickers (Brigg and Immingham) (Con)]

I welcome the Minister's statement. He will be aware that a routine prostate cancer screening programme would save many lives. Can he give any indication of when it will be introduced?

[Andrew Gwynne]

I am grateful to the hon. Gentleman for that question, and also for the written parliamentary questions about prostate cancer that he and a number of other Members have tabled. According to the current guidance, screening for prostate cancer is not recommended in the UK because of the inaccuracy of the current best test for prostate-specific antigen. Indeed, it could actually harm men, as some might be diagnosed with a cancer that would not have caused them problems during their lives. However, I am looking at this carefully, and I know that further information has gone to the National Institute for Health and Care Research so that it can, perhaps, reach a different conclusion. Obviously, as technology and other mechanisms advance, this may well be an area where we can make inroads, but I am happy to work with the hon. Gentleman to ensure that every opportunity is met.

[Josh Fenton-Glynn (Calder Valley) (Lab)]

I welcome this plan. I note that it was a recommendation from the Health and Social Care Committee in the last Parliament, and, as a member of that Committee, I hope that it sets a precedent.

Two weeks ago I lost my brother, Alex English, to high-grade acinic cell carcinoma. While I pay tribute to all those who gave him care, can the Minister confirm that we will look at rare cancers and make sure that we research some of them and find treatments?

[Andrew Gwynne]

First, may I send my condolences to my hon. Friend and his family on the loss of his brother Alex?

Of course rarer cancers are important, and they are a crucial part of what will be in the national cancer plan. It is in these areas that we must focus our efforts on diagnosis, treatment and, more importantly, getting the research done, so that we can find ways of tackling some of the very rare but deadly cancers that affect many families, including my hon. Friend’s.

[Wera Hobhouse (Bath) (LD)]

In 2013, the number of breast cancer cases in women under 50 topped 10,000 for the first time, but routine breast cancer screenings are given only to women aged 40 and over. Will the Department review that and ensure that, when appropriate, initial appointments can be given to younger women? While I am at it, although the Minister might not have time to attend, may I invite everyone else to swing by my drop-in event this afternoon to discuss local health inequalities in breast cancer?

[Andrew Gwynne]

I am grateful to the hon. Lady for the work that she does in this regard. The decisions on whom to screen are made by the UK national screening committee and their advice comes to Ministers, but I am aware of the case that she has made. Screening women earlier for breast cancer should perhaps be looked at, and I will ensure that my officials look into whether we can make some progress on that for her.

[Several hon. Members rose—]

[Peter Swallow (Bracknell) (Lab)]

Ethan was just 15 and studying for his GCSEs when he was diagnosed with a brain tumour. Sadly, he passed away two years later. I had the privilege of meeting his mum, Nikki, this weekend at two events organised to raise money for brain tumour research. In Ethan’s memory, will the Minister commit himself to improving outcomes for people with brain tumours through the national cancer plan?

[Andrew Gwynne]

Through my hon. Friend, I would like to pass my condolences on to Nikki for the loss of Ethan. As I have said, we have not made anything like the progress we would want to make on treatment and survival rates for brain tumours. That will form an integral part of our national cancer plan, and we will utilise all the latest advances in technology and science to try to get the better outcomes that we so desperately want.

[Greg Smith (Mid Buckinghamshire) (Con)]

I genuinely welcome the Minister’s commitment to the upgrading of radiotherapy machines, but I share the concerns of the chairman of the all-party parliamentary group on radiotherapy, the hon. Member for Westmorland and Lonsdale (Tim Farron), about the scale of the ambition. In defeating this horrible disease, technology and innovation is our friend. What is the Minister’s ambition for minimally invasive cancer therapies in the national cancer plan? These technologies are coming along every day, but awareness of them and the ability to get them rolled out on the frontline is slapdash at best. Will he commit to looking at those emerging therapies and getting them rolled out as soon as possible?

--- Later in debate ---

[Andrew Gwynne]

Absolutely. Things are advancing so quickly in technology and innovation. It is quite remarkable that science fiction is becoming science fact. We are obviously interested in minimally invasive therapies, and they will form part of the plan. That is why we are consulting. That is the purpose of this exercise: so that we can look at what technologies are here today, what the emerging technologies are and how they will shift the dial on some cancers.

[Adam Jogee (Newcastle-under-Lyme) (Lab)]

The House will know that my family, like many others in Newcastle-under-Lyme, has been impacted by cancer in recent times, so I thank the Minister for his statement and his personal commitment to getting this right. On World Cancer Day, I join him in paying tribute to the charities he mentioned in his statement, and particularly my constituents Mary and Colin, who raise so much money every year for Macmillan. Health inequalities in some of our poorest communities and our ethnic minority communities play a big role in cancer being diagnosed. Can the Minister tell me and my constituents in Newcastle-under-Lyme how we will tackle those health inequalities alongside this national cancer plan?

[Andrew Gwynne]

My hon. Friend makes a very good point, and it relates to not just cancer but a whole range of conditions, including cardiovascular disease, strokes and so many others—it is the same areas that have the worst outcomes, because there are endemic health inequalities that we have not shifted the dial on for decades. Life expectancy is much lower, and healthy life expectancy is much worse, than in less deprived areas. It is part of our health mission to drive forward better health outcomes for people living in the poorest areas, and our national cancer plan will be a key part of that.

[Dr Andrew Murrison (South West Wiltshire) (Con)]

In his remarks yesterday, the Minister for Data Protection and Telecoms, the hon. Member for Rhondda and Ogmore (Chris Bryant), implied that he was discussing the future with AstraZeneca, which has had some bad news this week. AstraZeneca makes immunotherapies, among other things, and therefore is very important in allowing people to live better for longer. What discussion will the Minister be having as part of his plan with the pharmaceutical sector, since plainly the national health service cannot do this alone?

[Andrew Gwynne]

The right hon. Gentleman makes a very good point. I have certainly had a number of roundtables with the pharmaceutical sector in the UK about how we can support it, how we can grow our life sciences sector and how Britain can be at the cutting edge of new treatments and clinical trials. Indeed, we had a Delegated Legislation Committee yesterday on regulations to make it easier to carry out clinical trials in this country. Some of the latest advances in pharma are quite remarkable; I think particularly of the work being done on mRNA technology to look at having specific cancer treatments pertinent to a person’s genomics—it could be a game changer.

[Sarah Smith (Hyndburn) (Lab)]

Hyndburn is home to the incredible woman Lorraine Hargreaves. She established the charity Milly’s Smiles after her daughter Milly died of leukaemia, and each year she supports thousands of families whose children have cancer. Can the Minister reassure her that this plan will also improve outcomes for children? I know that Lorraine will welcome the announcement on the re-establishment of the taskforce, but would the Minister consider meeting her to discuss the lack of support and grief groups for families who go through the unimaginable tragedy of losing a child to cancer?

[Andrew Gwynne]

I cannot even begin to think what it would be like to lose a child full stop, but to lose them to cancer would be horrific for their parents. I pay tribute to Lorraine for all the campaigning she has done on this. I am more than happy to meet my hon. Friend and Lorraine to talk about this, but the whole reason for putting the taskforce back on an operational footing is so that we can make the changes that she and Lorraine want to see.

[Freddie van Mierlo (Henley and Thame) (LD)]

Members across the House will be all too familiar with constituents reaching out to let them know that safe, effective new medicines are not approved by the National Institute for Health and Care Excellence. The Minister speaks of research and the need for access. Will he commit to being a critical friend of NICE, to ensure both good value for the taxpayer and good access for patients?

[Andrew Gwynne]

The hon. Gentleman makes a good point. NICE is there for a particular reason: to ensure that the drugs being developed are available on the NHS when they meet the required threshold. Of course, we want to ensure that as new treatments become available, they are available for British patients. The work that is being done with Moderna and other pharmaceutical companies will ensure that British patients have access to some of the latest treatments as they come through the pipeline.

[Katrina Murray (Cumbernauld and Kirkintilloch) (Lab)]

One of my earliest memories is being in a hospital room as my grandfather was dying of cancer. Ten days ago, I was in the same hospital as my father died with the same cancer—50 years in between, almost to the week, but no significant change in prognosis. Can the Minister assure me that what are termed the less survivable cancers, which are not necessarily rare cancers, are included as part of this work?

[Andrew Gwynne]

My heart goes out to my hon. Friend. I lost both my parents to cancer, and it does not matter when it happens in your life; it is just heartbreaking. As the children of those parents, you never get over it. Of course, we will have a concerted effort on less survivable cancers. In part, they are less survivable because the research has not been done, or not to the extent that we can develop better treatments for them. That is where we really have to shift the dial in the next decade. We have to make sure that people who have a cancer diagnosis have the best opportunities to live a long and fulfilling life after cancer.

[Paul Holmes (Hamble Valley) (Con)]

I declare an interest, in that I have now been smoke-free for 34 days using the NHS Quit Smoking app, even though my waistline and the Government have tested my resolve in recent weeks.

Eighteen months ago we lost my office manager, Susan Hall, to lymphoma. The Minister will know that parliamentary employees are not just employees; they are part of our family. Part of her treatment was community care provided by an excellent hospice in my constituency called Mountbatten hospice. This is not meant to be a political point, but what progress has been made on looking at a fairer, Government-led mechanism to fund our hospices across the United Kingdom on an even footing and with more money?

[Andrew Gwynne]

I congratulate the hon. Gentleman on being smoke-free. Hopefully, he is the first of many as we move towards a smoke-free UK by 2030. He makes a real and serious point about not just community care—one of the big shifts in the health mission is from hospital to community—but how we approach the hospice sector. Last weekend I was at my local hospice, Willow Wood in Ashton-under-Lyne, where staff made exactly the same point. That will be fed into the national cancer plan.

[Rachel Taylor (North Warwickshire and Bedworth) (Lab)]

I thank the Minister for his statement, and particularly for his deep understanding of women’s health issues and the difficulty that many women face in getting their GP to understand what they are going through. The Women and Equalities Committee has spent some time looking at that this year.

The George Eliot hospital in my constituency serves many of my constituents, who often complain about the length of time it takes to get scan results. Between June 2023 and 2024, almost 12% of people waited more than 28 days to receive MRI results, compared with 6.5% nationally. I know that the team there are working very hard to bring the time down, but can the Minister reassure my constituents that the use of AI will speed up the time it takes for them to get their scan results and the treatment they need?

[Andrew Gwynne]

My hon. Friend makes some really important points. The need to get people scanned more quickly, and to get results to consultants, is in part why we now have extra capacity through community diagnostic centres, where there are extra facilities for scans. She is absolutely right to raise the issue of where AI and emerging technologies may take us, which will almost certainly lead to faster identification of cancers.

[Robin Swann (South Antrim) (UUP)]

I thank the Minister for making his statement on World Cancer Day, and I do not doubt his sincerity on this issue. On 22 March 2022, the then Northern Ireland Health Minister launched a 10-year cancer strategy and funding plan. It was co-designed, co-produced and co-chaired by Professor Charlotte McArdle, the then chief nursing officer, and Ivan McMinn, the then chair of Cancer Focus NI. The strategy looked to adopt a regional approach, to create smoother pathways and to adopt successful innovations. It had 58 action points and was costed at £145 million per year for 10 years, but it has not really made any progress since the fall of the Northern Ireland Executive. The Minister has said that he is developing a national cancer plan. Will he meet me and the current Northern Ireland Health Minister to ensure that the work that was developed is not lost but is built into what can be a truly successful national cancer plan if we do it right?

--- Later in debate ---

[Andrew Gwynne]

I thank the hon. Gentleman for the work that he did in this area in a previous guise. I am more than happy to meet him and Mike Nesbitt, with whom I had a meeting on drug strategy and drugs as a public health issue before this statement, to drive forward how we can improve outcomes in Northern Ireland and get that plan working again, as it should never have stalled.

[Shaun Davies (Telford) (Lab)]

People talk about the politics of hope and, goodness me, this statement can give the country some hope that cancer survival rates will be driven up. However, the Shrewsbury and Telford hospital NHS trust has remained challenged over the last 14 years. Will my hon. Friend the Minister confirm that the areas that are most challenged will be given support to catch up and push on?

[Andrew Gwynne]

My hon. Friend makes a really important point, which is not lost on those of us on the Government Front Bench. There are real challenges across the healthcare system, and some of the areas with some of the worst outcomes also happen to have some of the worst health inequalities. Those issues are exacerbated by the pressure on the healthcare system. He can have my reassurance that the Government will make it a priority to drive down health inequalities and ensure that healthcare systems get the support they need.

[Vikki Slade (Mid Dorset and North Poole) (LD)]

I hope the Minister will join me in thanking the team at Dorset cancer centre in Poole, who enabled my step-mum, Sally Walls, to ring the bell this morning following the end of her radiotherapy treatment. Her treatment has been exceptional and swift, but the situation is inconsistent. Nikki from Horton was told that she needed a two-week appointment for gynaecological problems. When she called, she was told that it would be six weeks. She could not bear to wait, so she borrowed £650 to find out that she was all clear. Can the Minister offer reassurance that he will end the postcode lottery?

[Andrew Gwynne]

I congratulate the hon. Lady’s step-mum on ringing that bell, which is great news. The hon. Lady is absolutely right to raise the issue of inconsistency when it comes to the levels of service that different patients get. That will obviously be a major factor in the national cancer plan going forward, to ensure that all people diagnosed with cancer have the same levels of treatment and the same opportunities to survive.

[Jim Dickson (Dartford) (Lab)]

I warmly welcome the Minister’s statement. He will know as well as anybody else in this Chamber that smoking causes one in four cancers in this country, and that two out of three people who smoke will die as a result. He is assiduously moving the Tobacco and Vapes Bill through Parliament. Can he set out the likely effect that the Bill will have on those shocking statistics?

[Andrew Gwynne]

I am grateful to my hon. Friend for being a member of the Committee for that Bill, which ended its business last Thursday. The hon. Members for Sleaford and North Hykeham (Dr Johnson), and for Farnham and Bordon (Gregory Stafford), who are sitting on the Opposition Front Bench, were also members of that Committee. My hon. Friend is absolutely right, because the Bill will stop the conveyor belt that the tobacco industry has used to its advantage for decades. We are saying that we will not allow any more children and young people to become addicted to nicotine and tobacco, which, as he says, kills two out of every three users. It is uniquely the most harmful product, and we are making the next generation smoke-free for a reason.

[Claire Young (Thornbury and Yate) (LD)]

One of my constituents waited two years from the onset of severe symptoms to receive a cancer diagnosis, and another 10 weeks to have the type of cancer identified, at which point it was incurable. One of the key failings in this case seems to be the disconnect between her reporting the symptoms to her GP and getting the right referral to the hospital, despite her having a previous history of breast cancer. What promises can the Minister make on improving the co-ordination between different parts of the NHS to make sure that people like my constituent do not fall through the cracks in the future?

[Andrew Gwynne]

That kind of experience is unacceptable, and the purpose of our plan is to demand better of the NHS and the system more widely when it comes to cancer outcomes. Nobody should have the kind of experience that the hon. Lady’s constituent had, which is why we will drive better outcomes through better treatment and earlier diagnosis, and make sure that the whole NHS is joined up in the process—a key part of the national cancer plan.

[Douglas McAllister (West Dunbartonshire) (Lab)]

Given that today is World Cancer Day, this statement is extremely welcome. Half of all leukaemia patients will not survive beyond five years, and the outlook is even bleaker for those diagnosed with acute myeloid leukaemia. If no action is taken, 80% of those diagnosed with AML today will not survive this Parliament. Early diagnosis and greater research are key to improving people’s chances. Will the Minister consider introducing measures to ensure that they are included in the national cancer plan?

[Andrew Gwynne]

My hon. Friend has my assurance on all fronts there. Early diagnosis, more and better research, and identifying how we improve outcomes for people with a variety of cancers are all crucial. His points about leukaemia are well rehearsed in the Department and will be a key part of the national cancer plan.

[Mr Joshua Reynolds (Maidenhead) (LD)]

Some 3.4 million people in England live further than 45 minutes away from a radiotherapy centre. We all want to see that changed, but one of the challenges will be the fact that eight out of 10 radiotherapists have considered leaving the profession. Could the Minister outline what work the Government are doing to retain and recruit the radiotherapists that we need?

[Andrew Gwynne]

The hon. Member makes a reasonable point, and part of the reason that we are having a refreshed workforce plan alongside the 10-year NHS plan is precisely to address some of the concerns that he has raised. We need to make sure that we have the right workforce in the right place, and to future-proof it for the kinds of treatments that will come on stream in the coming decade.

[Dr Scott Arthur (Edinburgh South West) (Lab)]

I thank the Minister for his statement and also for the time he has spent with me discussing my private Member’s Bill, the Rare Cancers Bill. Yesterday, I met representatives of the Brain Tumour Charity, Brain Tumour Research and Pancreatic Cancer UK, and we did in part discuss the national cancer plan. I do not speak on those charities’ behalf, but one of the conclusions I drew from the discussion was that there is a real need to have the voices of rare cancer patients and survivors at the heart of this consultation. Does the Minister agree with that point? Secondly, on World Cancer Day, will he join me in wishing my daughter Ruth good luck as she trains to run a marathon in aid of the Brain Tumour Charity?

[Andrew Gwynne]

Good luck, Ruth! I hope she succeeds and raises lots of money for such a good cause. I want to thank my hon. Friend as well for his crucial work in this area. He has my assurances that at the heart of the first step, which is the call for evidence I have announced today, and of the development of the national cancer plan, those with lived experience—patients or loved ones of people who have had cancer and those who have either survived or are now bereaved—absolutely have to be at the heart of what we are doing. We will take their views, their opinions and their thoughts fully on board as we develop this plan.

[Max Wilkinson (Cheltenham) (LD)]

I lost my father to lymphoma and my wife is an ovarian cancer survivor, so I warmly welcome this statement. In Gloucestershire, we are a designated regional cancer centre, but unfortunately the buildings at Cheltenham general are just not up to scratch any more. Fundraising was mentioned earlier by the hon. Member for Mitcham and Morden (Dame Siobhain McDonagh), and we are in that situation. We need £17.5 million and we have £9 million to go. Will the Minister warmly congratulate the Big Space Cancer Appeal fundraisers, particularly Dr Charles Candish and Dr Sam Guglani, who are leading the charge on that? Would he like to meet those consultants to discuss how we might move this fundraising effort along so that the whole project does not rest on the back of charity?

[Andrew Gwynne]

I am more than happy to meet the hon. Member and the team to look at precisely those points and I wish them all the very best in their fundraising efforts, but look, as a country we are better than this. I want to see the national cancer plan really start to address how we can get that research, that treatment, those diagnoses and those better outcomes for people with the NHS at the heart of it, doing what the NHS does best and ensuring that we get those outcomes from publicly funded improvements.

[Sojan Joseph (Ashford) (Lab)]

I welcome all the efforts this Government are making to improve cancer services. Early diagnosis is just as important as prevention, but we all know that patients are currently waiting several months for scan procedures. A recent visit to the GP surgeries in my constituency showed that they have spare capacity for scanning, but it is not actively offered to patients at the moment. This is due to a lack of collaborative working and communication in the health system, so will the Minister tell the House how we can improve the existing systems so that they work effectively and people can get timely procedures?

[Andrew Gwynne]

Part of our recovery plan is to ensure that we return the national health service to constitutional standards, not just in respect of cancer but across the board. We inherited a broken national health service and it is incumbent on this Government to fix it and make it fit for the future. Clearly, in areas such as my hon. Friend’s, the NHS needs to be doing much better when it comes to cancer outcomes and cancer treatments, and this plan and this Government will ensure that his local system gets all the support it needs.

[Clive Jones (Wokingham) (LD)]

I declare an interest, as I have a family member who has shares in a medical company.

I pay tribute to the Minister for following through with his promise for a national cancer plan. It is clearly very important to him, and it is to me as well. Shaun Walsh of Cancer Research UK first raised with me the need for a dedicated cancer plan, and it has been an important part of my work in Parliament since then. Will the Minister meet me and Shaun to discuss the next steps for the national cancer plan?

[Andrew Gwynne]

I am more than happy to do so. My diary secretary, who will be watching this from the Department of Health, is probably having kittens at the amount of meetings. I meet Shaun and the cancer charities frequently anyway, and as I said at the start of the statement, I commend the work that they do in this area. This national cancer plan is important to me, to the Secretary of State, to the Prime Minister and to the sector, and that is why we are doing the right thing and having a plan.

[Steve Yemm (Mansfield) (Lab)]

I welcome today’s statement and I know that my wife, Julia, who is a consultant radiographer in mammography at King’s Mill hospital, will also welcome it. One of my earliest childhood memories is of watching my grandfather, William Yemm, die of lung cancer. William was a lifelong coalminer at Blidworth colliery. I think he drank and smoked rather more than was good for him throughout his life, so does the Minister agree that prevention is every bit as important as diagnosis, treatment and research in the fight against cancer? Can he reassure me that this welcome national cancer plan will consider what action we can take to prevent people from developing cancer?

[Andrew Gwynne]

My hon. Friend raises such an important point. This Government have three shifts and I have mentioned two of them already: the shifts from hospital to community and from analogue to digital. The third shift is from sickness to prevention. We absolutely have to shift the dial, whether it is on alcohol harms, smoking, obesity, inactivity or the air we breathe. These are the five-point plan priorities when it comes to prevention. My hon. Friend is so right to focus on this, and we hope to cut the instances of a whole range of preventable illnesses, including cancer.

[David Chadwick (Brecon, Radnor and Cwm Tawe) (LD)]

Many of my constituents have to travel to England to access cancer treatment. This presents many problems, one of which is a lack of data sharing between NHS England and NHS Wales. Will the Minister assure Welsh patients that if they are treated in an English hospital, their data will follow them home and that it will be accessible to NHS Wales?

[Andrew Gwynne]

The hon. Gentleman raises an important point. I also have regular meetings with ministerial colleagues in the Welsh Government, and this is an area of interest to both Governments. We need to make sure there is better sharing of data and information for patients from Wales, Scotland and Northern Ireland when accessing NHS services in England, so that there is joined-up, smarter use of the data held on patients by our respective NHS systems in order to get better outcomes. I assure the hon. Gentleman that I am already taking this up with ministerial colleagues across the devolved Administrations.

[Paul Davies (Colne Valley) (Lab)]

I thank the Minister for his statement. Since my election, I have met a wide range of cancer charities, especially those representing rare and less common cancers. As the Minister knows, 55% of UK cancer deaths are a result of those types of cancers, such as blood, ovarian and kidney cancers. Will he ensure that rare and less common cancers are not forgotten in the national cancer plan?

[Andrew Gwynne]

My hon. Friend has my full assurance that all cancers—all tumour types—will be an integral part of the national cancer plan. On rarer cancers, it is important that we use the call for evidence and the discussions we will have in the coming weeks and months to ensure that those voices are heard as we drive forward our plan.

[Jim Shannon (Strangford) (DUP)]

I thank the Minister for his statement. His words always display the compassion and comfort that these types of statements should convey.

Does the Minister agree that it is time for the Government to do more to fund cancer research, rather than leaving charities to bear the burden? Cancer Research UK alone has invested more than £4 billion in research over the last 10 years. Will this plan ensure that groundbreaking research, such as that carried out at Queen’s University Belfast, will have enhanced funding for a world-class breakthrough in finding a cure for cancer? Will Northern Ireland be one of the UK’s 30 testing sites for women?

[Andrew Gwynne]

I thank my hon. Friend. I always call him my hon. Friend because I see more of him than I see of my wife. [Laughter.] Usually because we are in the same debates.

The hon. Member makes an important point about research, which will be a crucial aspect of the national cancer plan. Advances in technology, science and pharmaceuticals do not happen by accident; they happen because we fund the research to get to that point. We need to do much better in researching some of the rarer and less survivable cancers. Those scientists and charities must have access to the funds that are available so they can carry out the research we need.

As for where the 30 sites will be, that is above my pay grade. There are criteria, but I will take it back to my officials and see what we can do.

[Chris Vince (Harlow) (Lab/Co-op)]

I thank the Minister for his statement, and I thank every Member on both sides of the Chamber who has shared their personal stories.

I was nine years old when I lost my grandmother, Grace, to cancer. That was a long time ago, but it still has a profound effect on me. Does the Minister agree that early detection is vital for survival rates? In particular, I emphasise the point about the importance of ensuring that women are taken seriously when they visit their GP.

I thank my constituent Sir Rod Stewart for the support he gave to the radiography department at Princess Alexandra hospital. Does the Minister agree that this national cancer plan will mean that we do not have to rely on the good will of rock legends such as Rod Stewart to support everyone in our society?

[Andrew Gwynne]

Talk about name-dropping; if only I had such famous constituents. Burnage was once home to the Gallagher brothers, and Denton was home to Mick Hucknall—I do not think any of them live there any more.

My hon. Friend makes an important point that women, in particular, have to be taken seriously by their GPs. The symptoms of some of these cancers could indicate a multitude of different things but, knowing from my mum’s bitter experience, I would sooner that GPs erred on the side of caution and got people diagnosed. If the diagnosis turns out not to be cancer, what a wonderful result that is. If it is cancer, we can get them on the treatment pathway sooner rather than later.

[Mr Bayo Alaba (Southend East and Rochford) (Lab)]

I also commend the Minister for his great announcement, which is welcome and needed.

The Minister has often spoken about the importance of shifting from sickness to prevention, from hospital to community, and from analogue to digital. Residents of Southend East and Rochford deserve an NHS that is there when they need it. What impact does he think the plan will have on the issues he has outlined today?

[Andrew Gwynne]

My hon. Friend raises an important point, and it is a good one on which to end. Each of those three shifts—from hospital to community, from analogue to digital, and from sickness to prevention—could be taken in isolation. However, by putting them together, we can shift how we deliver health and care in this country. We will make it fit for purpose, we will drive up standards across the system, we will get the NHS back to constitutional standards—which means lower waiting times, shorter waiting lists and better outcomes—and, when it comes to cancer, we will save lives. It is as simple as that.

Bill Presented

Statutory Adoption Pay (Report on Extension to the Self-Employed) Bill

Presentation and First Reading (Standing Order No. 57)

Lisa Smart presented a Bill to require the Secretary of State to report to Parliament on the merits of extending eligibility for statutory adoption pay to persons who are self-employed or contractors; and for connected purposes.

Bill read the First time; to be read a Second time on Friday 7 March, and to be printed (Bill 175).

Draft Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2024

Andrew Gwynne Excerpts

Monday 3rd February 2025 General Committees

[The Parliamentary Under-Secretary of State for Health and Social Care (Andrew Gwynne)]

I beg to move,

That the Committee has considered the draft Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2024.

It is a pleasure to serve under your chairmanship, Sir Desmond.

I am grateful for the opportunity to debate these important amendments, which represent the most significant reform of UK clinical trials regulation in more than 20 years. Clinical research is the single most important way in which we improve our healthcare, by identifying the best way to prevent, diagnose and treat conditions.

Clinical trials are vital for patients with limited available treatment options, such as the estimated 3.5 million people living with rare diseases in the UK, together with the 17.5 million living with long-term conditions. This draft legislation will play a vital role in supporting the development of new treatments for those who so desperately need them by transforming the environment for clinical trials in the UK.

The changes respond to the sector’s need for a more efficient and adaptable regulatory framework, while safeguarding the wellbeing of trial participants. The reforms will establish a proportionate, flexible and effective clinical research environment, placing patients at the heart of the process. The changes have been carefully designed in response to calls for reform, aligning with the direction set in our manifesto promise to build an NHS fit for the future and maximising the UK’s potential to lead the world in clinical trials.

The reforms are further underpinned by the findings of Lord Darzi’s independent investigation of the NHS in England and the recommendations of Lord O’Shaughnessy’s review into commercial UK clinical trials. These changes to modernise the regulatory framework will cement the UK as a destination for clinical trials that is innovative, inclusive and international and will, most importantly, help to get life-changing medicines to the people who need them sooner.

Let me explain to the Committee why Government believe change is needed. It is necessary and timely. The existing legislation is based on the now repealed and replaced European Union clinical trials directive. It no longer reflects the rapid advancements in medicine and technology. We have the opportunity to reform our national regulations to deliver a world-class regulatory environment for clinical trials, supporting the safe development of innovative treatments benefiting patients and public health alike.

I will now briefly summarise the key aspects of the reforms. Of the key changes, the first is risk-proportionate regulation. Regulatory requirements will align with the risk level of a clinical trial, empowering researchers to adopt appropriate approaches. Low-risk clinical trials will benefit from faster approval processes through automatic authorisation, without compromising patient safety.

Secondly, there is future-proofing: the draft legislation is a purposeful move away from a one-size-fits-all approach, which does not reflect modern, innovative clinical trial methods. We have removed granular and duplicative legal requirements in favour of specific, tailored guidance, which will provide flexibility and adaptability for future advancements.

Thirdly, there is international alignment: the United Kingdom will remain aligned with international standards to ensure that data from UK trials is accepted globally. That will help to secure the UK’s place as a preferred site for multinational clinical trials, including those conducted across the European Union.

Fourthly, this new framework will cement the UK as a destination for international clinical trials. Streamlined and efficient processes will be introduced to simplify clinical trial applications. The legislation will include a combined regulatory and research ethics review, ensuring that approval timelines are internationally competitive.

Finally, there is increased transparency. We want to ensure that trusted information about clinical trials is publicly available for the benefit of all. The changes will, for the first time, introduce a legal requirement to register a clinical trial and to publish a summary of the results. Participants will be offered an easy-to-understand summary of what the research has found out. These new transparency requirements will build public trust in research, and ensure that participants, and the wider public, have access to information about ongoing research and can use research findings to help to make informed decisions.

I will now turn to the benefits of this new framework in more detail. Patients will have greater access to life-changing treatments, which will improve outcomes and save lives. These reforms ensure that UK patients will be among the first to benefit from cutting-edge therapies. The transparency requirements will ensure that trusted information about clinical trials is publicly available for the benefit of all, improving public trust and confidence in the innovative clinical trials taking place in our country.

Evidence also shows that hospitals that undertake research have better patient care outcomes and improved staff retention, and that it benefits the whole health and care system. Clinical trials are part of the solution for reducing the strain on our National Health Service. Improved efficiency in conducting clinical trials will enhance research efforts and foster innovation in prevention, diagnosis and treatment across various conditions.

Additionally, we are broadening the categories of healthcare professionals who can be accepted as investigators, encouraging more researchers to carry out clinical trials in their specialist areas. Innovators and industry will run clinical trials within a streamlined, risk-proportionate regulatory framework, with reduced delays and administrative burdens, which will support industry growth and bolster the UK’s life sciences sector—something that I am sure Members on both sides of the House support.

The impact on businesses has been evaluated; as the projected costs and benefits to businesses was below £5 million in any single financial year, a full impact assessment was not required, as originally stated in the accompanying explanatory notes. Instead, a de minimis assessment was produced and is published alongside this instrument.

To summarise, this new framework uses effective regulation to accelerate the development of medicines, turning tomorrow’s emerging medicines into today’s reality for patients. By modernising our approach, we can solidify the United Kingdom’s position as a global leader in clinical research, fostering innovation while upholding the highest safety standards.

I want to end on a critical point: participant safety remains paramount. This new legislation, while streamlining processes and removing unnecessary barriers to innovation, prioritises robust oversight of clinical trials, ensuring that the safety of those participating in a trial is never compromised. I therefore commend these draft regulations to the Committee, and I hope that hon. Members will join me in supporting these transformative changes.

--- Later in debate ---

[Andrew Gwynne]

I thank the shadow Minister for her support for this piece of secondary legislation, which marks the most substantial update to UK clinical trial regulations in more than two decades. This is an important step forward to deliver a more efficient and adaptable regulatory framework, all while ensuring the safety of the trial participants. The reforms will deliver a proportionate, flexible and efficient clinical research environment, with patients at the very heart of the process.

The shadow Minister raised the issue of AstraZeneca and the support for life sciences in the UK. Without straying too much from the measures before us, Sir Desmond, I want to reassure the Committee that this Government are fully committed to supporting the UK’s life sciences sector. Today we have heard about how vital clinical trials are in driving the health and wealth of the UK. The sector has experienced strong growth in recent years; between 2022 and 2023, the number of UK industry-led clinical trials increased by 3.7%. The UK has also gone up in the global rankings for phase 2 trials, moving from sixth to fourth place.

That progress is a testament to our thriving research ecosystem, something that was developed under the previous Government and that we want to build on, which is what this set of regulations is all about. They are about making sure that our country is at the cutting edge of the latest developments in medical science and that British patients are able to access those treatments as early as possible, through clinical trials and then through the early adoption of those medicines once they are brought to market.

The shadow Minister asked about the de minimis assessment. An assessment of the updated legislation has been produced, which estimates that there will be a total transition cost of approximately £720,000 to business for organisations to familiarise themselves with and operationalise the changes. It is expected that the annual total benefit to businesses will be £1 million, primarily due to the changes in the approval processes. I sought to correct the record in my opening remarks because it had originally been anticipated that we would need to have the full assessment, but on closer scrutiny that is not necessary because of the reasons that I have just set out.

[Dr Johnson]

When the Minister talks about £1 million, is that the benefit to businesses in the current level of trials? Or is that his estimate of the rise in the number of trials as a result of the changes?

--- Later in debate ---

[Andrew Gwynne]

That is my understanding—I look for inspiration if I am wrong—of the situation today. If that is not correct, I will ensure that the hon. Lady and members of the Committee are informed in writing. The impact on businesses is the impact on business as it stands now, but we want to grow the business and ensure that the ecosystem grows and that the life sciences sector is booming in this country, for all the reasons that I set out in my opening speech.

In conclusion, by modernising our regulatory framework we will ensure that lifesaving treatments are accelerated by streamlined, efficient processes without compromising safety standards. The reforms will strengthen the UK’s position as a global leader in innovative clinical trials and help to get lifesaving, life-changing medicines to the people who most need them sooner. I am grateful to the shadow Minister for her support and to Members for considering the regulations today; I hope they will all join me in supporting them.

Question put and agreed to.

Tobacco and Vapes Bill (Thirteenth sitting)

Andrew Gwynne Excerpts

Committee stage
Tuesday 28th January 2025 Public Bill Committees

[Dr Johnson]

I know my hon. Friend is very interested in AI. I am sure that if it is possible to do so, these industries will use any means available to them to maintain their market.

The clause extends the regulations from tobacco to cover all vaping products, herbal smoking products, cigarette papers and nicotine products. Given my concerns about children and vaping and the use of nicotine, I think this is a sensible measure, which I support.

[The Parliamentary Under-Secretary of State for Health and Social Care (Andrew Gwynne)]

It is a pleasure to serve under your chairmanship, Mr Pritchard. Clauses 126 and 127 and schedule 16 contain provisions relating to audiovisual services and radio broadcasting. Clause 126 provides that part 6, which deals with advertising and sponsorship, does not apply to certain categories of television and radio service. That is because these services are already prohibited under the Communications Act 2003.

Clause 127 introduces schedule 16, which amends the Communications Act 2003. The amendments extend provisions in that Act that ban advertising and sponsorship of tobacco products in certain TV and radio services to include herbal smoking products, cigarette papers, vaping products or nicotine products. That ensures that the advertising ban on tobacco in television, radio and on-demand programme services is extended to all of those products. In practice, the measure means we will no longer see banned products or promotional material for those products on any of those mediums.

The shadow Minister rightly points out that the services listed in the clause include ITV, independent television and radio, the BBC and Sianel Pedwar Cymru, and on-demand programme services—that covers the points that Members have made—and non-UK on-demand programme services, which are tier 1 services as defined in the Communications Act 2003. I hope that reassures the hon. Member for Farnham and Bordon that it also includes programmes produced and aired outside the United Kingdom that are brought into the United Kingdom.

As a helpful aide-mémoire for the Committee, the Communications Act 2003 regulates telecommunications broadcasting. It confers functions on the Office of Communications, a regulator, to oversee the services. The Act puts in place effective rules for the advertising of tobacco on television, radio and on-demand services. By amending the Act, we ensure that this existing framework also applies to vaping products, nicotine products, and cigarette and herbal smoking papers. There is no need to reinvent the wheel and add more to the Bill, as we can use the existing provisions in the 2003 Act. I therefore commend the clauses to the Committee.

Question put and agreed to.

Clause 126 accordingly ordered to stand part of the Bill.

Clause 127 ordered to stand part of the Bill.

Schedule 16 agreed to.

Clause 128 ordered to stand part of the Bill.

Clause 129

Enforcement authorities

Question proposed, That the clause stand part of the Bill.

[The Chair]

With this it will be convenient to consider clauses 130 and 131 stand part.

--- Later in debate ---

[Andrew Gwynne]

I thank the shadow Minister for her questions. The Government are investing over £100 million over five years to boost His Majesty’s Revenue and Customs and Border Force’s enforcement capability to tackle illicit tobacco. In 2025-26 we will invest £30 million of new funding for enforcement agencies, including trading standards, Border Force and HMRC, to tackle illicit and under-age sales of tobacco and vapes, supporting them to implement the Bill.

Decisions on funding for trading standards in future years will be made as part of the spending review process, but given our clear commitment to enforcement in the Bill and the fact that we have put down the payment of £30 million for enforcement in the next financial year, I hope hon. Members are assured that we take these matters seriously. We are investing £3 million over two years specifically to enhance the work led by National Trading Standards to tackle under-age and illicit vape sales. That work is carried out through enhancing market surveillance and enforcement action on ports, online sales enforcement, and boosting the storage and disposal of illicit vapes. The new funding for 2025-26 will build on this work to tackle under-age and illicit vape sales.

The shadow Minister asked how trading standards will use their additional enforcement funding. The crucial point is that we want to boost trading standards’ capacity, to enable the services to conduct more under-age sales test purchases, remove illicit products from the market and identify non-compliant products and bring them into compliance where possible.

[Dr Johnson]

My question was not simply how trading standards will use the money allocated, but whether the Minister feels that the money he has allocated is adequately purposed?

[Andrew Gwynne]

I do, which I have just said. The £30 million in the next financial year to boost the enforcement agencies will meet the needs that the Bill sets out. It is also about boots on the ground and having greater capacity. We will be working with trading standards on this additional enforcement funding to ensure that they increase their capacity and are able to take on the roles and responsibilities that the Bill places on them. We will continue to discuss with trading standards how we can best support them in respect of the measures of the Bill. I commend the measures to the Committee.

Question put and agreed to.

Clause 129 accordingly ordered to stand part of the Bill.

Clauses 130 to 132 ordered to stand part of the Bill.

Clause 133

Power to extend Part 6 and Communications Act 2003 to other products

Question proposed, That the clause stand part of the Bill.

[Dr Johnson]

Clause 133 gives the Secretary of State the power to extend part 6, which deals with advertising and sponsorship, and the Communications Act 2003 to other products, specifically products that are devices of a specified description enabling a tobacco product to be consumed, such as a heated tobacco device or pipe, or an item that is intended to form part of such a device. It allows the Secretary of State to consult with the required persons and gain consent where required with the devolved legislatures. However, how will the Secretary of State further define that, and can the Minister give us some examples of the types of products that might be included under the power? Could it allow for the expansion of regulation to a wide range of products not originally envisaged in the Bill?

The inclusion of devices and items potentially covers a wide array of consumer products without any clear boundary. What are the specific criteria or considerations that the Secretary of State must use when deciding whether to extend the provisions? Could that lead to arbitrary or inconsistent decision making, depending on the political or public health priorities of the Government of the day? The wording seems to give considerable latitude, but not much clarity on when or how the Secretary of State should exercise the power.

[Andrew Gwynne]

I am very happy to answer the question posed by the shadow Minister. It is a simple answer: we need clause 133 to avoid loopholes. Otherwise, newer products such as heated tobacco—and those products that have not even been developed yet—are in scope of the restrictions, but devices used alongside them could still be used to promote tobacco consumption.

Question put and agreed to.

Clause 133 accordingly ordered to stand part of the Bill.

Clauses 134 and 135 ordered to stand part of the Bill.

Clause 136

Addition of smoke-free places in England

[Jim Dickson (Dartford) (Lab)]

I beg to move amendmentusb 11, in clause 136, page 77, line 8, after “regulations” insert

“and a local authority may (as respects its area) make byelaws”.

This amendment would extend the power to designate areas as smoke-free to certain local authorities, by making byelaws. Any byelaws so made would need to be confirmed by the Secretary of State by virtue of section 236 of the Local Government Act 1972.

--- Later in debate ---

[Dr Johnson]

Amendment 14 defines a local authority as

“a county council…a district council, a London borough council, the Common Council of the City of London in its capacity as a local authority, the Council of the Isles of Scilly, a combined authority or a combined country authority.”

By the time we get to next summer, Lincolnshire will probably have district councils, a county council and a mayoral authority—I do not agree with having a mayoral authority, because I think that is too many tiers of government, but that is an aside. What if those authorities do not agree? If we give them all the power to make regulations, they could all make different regulations based on different opinions—as is currently the case in Lincolnshire, the various authorities are not always under the control of the same political party.

[Andrew Gwynne]

I am grateful to my hon. Friend the Member for Dartford for bringing this issue before the Committee. As we have heard, amendment 11 would introduce a power for local authorities to make byelaws relating to the designation of additional smoke-free places in England, which would sit alongside the Secretary of State’s power to make regulations in the same regard.

As we know, the Bill expands the Secretary of State’s powers to create additional smoke-free places at the national level. In England, the Government have already indicated that we intend to extend the smoke-free designation to outdoor places including children’s playgrounds and outside schools and hospitals, but not to outdoor hospitality settings or wider open spaces such as beaches. The reforms we are setting out in the Bill will be subject to full consultation, and we want to hear the views of people from across the country to ensure that we get them right.

As drafted, the Bill gives no additional powers to local authorities. However, they have existing mechanisms for designating certain spaces as smoke-free. As we have heard, areas such as Manchester, my home city, have already used pavement licensing provisions to ensure that people have smoke-free options when they consume food and drink in certain locations, and that works well. Some local authorities have implemented public space protection orders to prohibit smoking in certain areas. For example, the London borough of Enfield has used a public spaces protection order to restrict smoking within the boundaries of children’s playgrounds. Of course, that will be obsolete should the consultation for the national scheme extend to children’s playgrounds, as we intend it to.

[Dr Caroline Johnson]

I thank the Minister for making those interesting points. Can he clarify whether powers such as those enacted in Enfield create a criminal offence?

[Andrew Gwynne]

We want to ensure that people who are smokers are not criminalised. Public space protection orders do potentially go down the criminal route. We want to ensure that that is not the case, which is why the Enfield scheme would of course be obsolete under the later provisions—which we are going to discuss today, hopefully—in relation to extending national outdoor smoke-free places.

[Dr Danny Chambers (Winchester) (LD)]

It is reassuring to hear the Minister talk about consulting before bringing in smoke-free places in specific public outdoor areas. Personally, as a non-smoker and someone who is very concerned about the public health impacts of passive smoking, I think we must also be mindful of the need for evidence-based interventions, and of the trade-offs. A good example is that of some fantastic pubs around Winchester and the Meon valley that have maybe two beer gardens, one to the side and one to the back. There would genuinely be no public health risk if smoking was permitted in one of the beer gardens and not the other.

The Liberal Democrats want reassurance on that. One of the reasons we tabled our amendment to clause 136, which is coming up, is simply to get assurances that the hospitality sector will not be impacted by any of these decisions, especially if the public health benefits are negligible.

[The Chair]

Order. We will discuss the specifics of the hon. Gentleman’s amendment when he moves it.

[Andrew Gwynne]

I suspect we are straying off the measures before us, Mr Pritchard, but I assure the hon. Gentleman that consultation is a statutory duty in this Bill. Were the Secretary of State, or indeed Welsh, Northern Irish or Scottish Ministers, to seek to change the scope in the future, they would have a duty at every stage to consult further. I hope that reassures the hon. Gentleman.

I was talking about Enfield and its public spaces protection orders. It is of course for the local authority to determine whether a PSPO is appropriate and that the legal test for implementing a PSPO is met, along with completion of the relevant consultation requirements. Nottingham has created a voluntary smoke-free zone at events, especially those where children are present, and it introduced a smoke-free play park policy in 2015. Other local authorities, such as Oxfordshire county council, have introduced voluntary smoke-free school gates policies. Given the options already available to local authorities and the national reforms introduced through this Bill, which we will debate further, neither the Government nor I think it is necessary to grant these byelaw-making powers via the Bill.

In answer to a point that the shadow Minister raised, which I hope to answer for my hon. Friend the Member for Dartford, legislation sets out all the different types of local authority. Enforcement in terms of the requirement to police any changes would appertain to the particular local authority, because it would be on that local authority’s land that the measures would apply. For example, in a two-tier area, if the county council as the highways authority deemed that pavement licensing were to be introduced, it would be for the county council to enforce its own measures; if a district council brought in measures in a park for which it was responsible, it would be for the district council. I think that is quite a simple explanation.

I understand that we have a complex jigsaw of local government, but it is for the particular type of council or authority that introduces a measure to enforce it. For example, the pavement licence in the City of Manchester is for the City of Manchester to enforce—not Andy Burnham as the Mayor of Greater Manchester, or indeed the Greater Manchester combined authority. That is pretty simple.

[Dr Johnson]

My question was not so much about the enforcement, which is defined in the Bill as the local weights and measures authority. Amendment 11 says that a local authority may make byelaws. The local authority that may make these byelaws includes the whole range of county councils, district councils and combined authorities, implying that, whoever is enforcing it, those that could make a byelaw could overlap and have contrary views.

[Andrew Gwynne]

Obviously, if a local authority introduces byelaws, as the City of Manchester has done in respect of pavement licensing, it is for that local authority to ensure that those byelaws are adhered to. Of course, in that case, the weights and measures authority is the City of Manchester, so I suppose that makes it easier.

These powers are already being used. Local authorities are already designating areas, whether it is for pavement licences, public space protection orders or just deeming that land within their own responsibility is smoke-free. We do not believe that the amendments are necessary. I kindly ask my hon. Friend the Member for Dartford to withdraw them.

[Jim Dickson]

The Minister has given a very comprehensive response. I suspect that the suggestion that this might be a way forward might come up in the consultation when that happens in the coming months. For the moment, I beg to ask leave to withdraw the amendment.

--- Later in debate ---

[Sarah Bool]

I respect the points made by the hon. Member for Cardiff West, because I understand that we do not want any unintended consequences. However, I would counter that by saying that although we perhaps need better definitions—that may be something we can consider—clause 136, as drafted, is incredibly wide, and any of the assurances that have been given to hospitality are merely words. There is absolutely no carve-out for the hospitality sector as this stands.

As much as I think the Minister is honourable in his intentions, unfortunately, we all know that we can go only on the law in front of us in black and white, and there is currently no security for the hospitality sector in this regard. We need to be incredibly clear about this with the hospitality sector, and we need the exclusion. One of the bigger concerns is that if people are not able to smoke—perhaps in a pub garden—it will force them into their homes, where they are actually more likely to drink and smoke more because they are not within that limited capacity of being out in public. We have to think about what the dangers are. Are we actually forcing people to take up worse habits in their private residence than if we allow them a little bit of flexibility in an open space?

I have a question about NHS properties generally. I appreciate that we want smoke-free places and that one wants to go into hospital and walk past people smoking, but I worry about those who have an addiction. Where do they go if they need to smoke, as they would if they are going through a process of cessation? What ends up happening as a result of all these provisions is that the smokers will just be forced down the road away from the property, but that has not really addressed the issue. We have just pushed the problem a few metres away.

We need to think in the round about how we best achieve our aim, how we deal with addiction, and how we clean up the hospital environment in a balanced and proportionate way. Perhaps the Minister has some other ideas, but I do not like the idea of just pushing some smokers down the road, rather than dealing with the issue at hand.

[Andrew Gwynne]

I am grateful for our debate on amendments 4, 94 and 95. I am even more grateful that a lawyer, my hon. Friend the Member for Cardiff West, is sitting behind me—as a non-lawyer, I note that it is always good for somebody to have one on their side. Indeed, the hon. Member for South Northamptonshire is a lawyer as well; in matters of law, there are always disagreements.

Amendments 4 and 95 would remove the power in the Bill to extend smoke-free places to any area that is a workplace or open to the public, including outdoor spaces in England. That would be replaced with a limited power to extend smoke-free places only to healthcare and education settings and to playgrounds. Amendment 94 would reinstate the test present in the Health Act 2006, which requires, in the Secretary of State’s opinion, a significant risk of exposure to significant quantities of smoke before being able to designate an additional place as smoke-free.

On extending smoke-free places, as we heard from a range of public health experts, evidence for the harm from exposure to second-hand smoke is well established. People exposed to second-hand smoke are at increased risk of cancer, chronic respiratory disease and cardiovascular disease. The World Health Organisation estimates that, every year, second-hand smoke kills up to 1.3 million people worldwide.

The science tells us three things about second-hand smoking. First, it poses a risk to health even outdoors. Secondly, it is particularly dangerous for vulnerable people, including children, pregnant women and those with pre-existing but usually invisible health conditions, such as asthma and diabetes. Thirdly, in some public settings, exposure to second-hand smoke can be high. If you can smell it, you are inhaling it.

It is important that the powers are broad, so that the Bill is appropriately future-proofed, as we have discussed in relation to other measures in the Bill.

[Gregory Stafford]

The Minister may come to this, and I am sorry to keep banging on about it, but I do not understand the future-proofing element of the clause and, therefore, why he opposes our amendments. Unless we have colonised Mars, surely there will be no new definition of an open space, or new wonderful industry way of claiming there is one. We know what open spaces are, and they are not going to change, so what is the future-proofing element?

[Andrew Gwynne]

The future-proofing element is if the science changes or, more likely, that over time public attitudes change. Smoking is already a minority pastime, and we expect that, in 25 years’ time, the prevalence of smoking among those aged 30 or below will be near to zero, so we will want to protect people from the scourge of second-hand smoke in other places. But that is a debate for other Ministers in other Sessions of other Parliaments at some stage in the future.

I do not want to tie the hands of my successors, so that they have to find a slot before the House for primary legislation to make simple changes. A far more practical and workable mechanism is for my successors to be able to come to the House to say, “The evidence has changed”, or, “Public opinion has changed”, and, “We now seek to consult the outside world on introducing further areas under the powers in the Bill”, and then to lay secondary legislation following the statutory duty to consult. Other areas can therefore come within the scope of the Bill.

[Sarah Bool]

I take the Minister’s point, but there is only a requirement to consult, so actually, completely unlimited powers have been given to make this change. We are trying to argue that we want the spaces to be clearly defined. It is important and right that we should come back to Parliament to make a change at a future point, if we want to extend the Bill further. But that will only be consultation, based on the current drafting, and a change could be pushed through regardless. The Labour party says that it is trying to support and back hospitality, so making this absolutely clear on the face of the Bill at this point will give hospitality the reassurance that it needs. I cannot see why there is any objection to more clarity, rather than overarching and wide powers. We are binding the hands of future generations and telling them that they cannot smoke and cannot vape—that right has gone—and then, on the other hand, we are saying, “I cannot bind the hands of my future successors”. We need reassurance and clarity for hospitality, and that is not in the Bill.

[Andrew Gwynne]

I have at no stage said that Ministers would not come back to Parliament. What I have said is that we should not be seeking to find one of those rare things—a slot in a King’s Speech for primary legislation—for something as simple as consulting on further areas.

I also remind the hon. Lady that the powers in the Bill are UK-wide. They do not give just the Secretary of State, or me as the Public Health Minister, the powers to consult in relation to England; they give the same powers to the Scottish Health Minister, the Welsh Health Minister and the Northern Irish Health Minister to consult and to bring forward secondary legislation on extensions following that.

We have been absolutely clear that the Government intend, in relation to England, to consult on schools, hospitals and children’s playgrounds—nothing else. It is those three things. That is our intention. The level of detail will be subject to the consultation. If in the consultation it is deemed that the measure should be extended to other NHS facilities beyond hospitals or to nurseries as part of an education setting, that will be entirely a matter for the consultation, and secondary legislation will therefore be brought to this House. But it is our intention—I cannot make it any clearer—that the three areas this Government are going to consult on are hospitals, outside schools and children’s play areas. We are not going to consult on hospitality. That is clear.

My counterparts in other parts of the United Kingdom may well come to a different decision on which areas to consult on. They may not consult at all.

[Gregory Stafford]

I thank the Minister for his clarity about what he and the Secretary of State are going to consult on; I take him at his word, of course. But is he not now demonstrating the concerns that we have? Other parts of the United Kingdom will potentially consult on retail. Therefore, the amendment is absolutely necessary. Although I am an England Member of Parliament and care mostly about the good people of Farnham, Bordon, Haslemere, Liphook and the surrounding villages, I have a wider duty as a Member of Parliament to ensure that the hospitality businesses of the United Kingdom of Great Britain and Northern Ireland are protected. I am afraid that the Minister has really worried me with what he has just said.

[Andrew Gwynne]

I can speak only for England, but I am legislating for the United Kingdom with the permission of Health Ministers. It may well be that Health Ministers in other parts of the United Kingdom decide not to consult at all. In Wales, for example, they already have the coverage of all the areas that we are going to consult on in England.

The hon. Member for Farnham and Bordon says he is now even more worried. Well, I tell him this: worry not, because his amendment relates to England only. If he is so mithered about the rights of the Welsh to consult Welsh business on Welsh matters, he should have put Wales in his amendment. If he so bothered about the rights of the Scots to consult on Scottish matters with Scottish business, he should have put Scotland in his amendment. If he is so bothered about the rights of the Northern Irish to consult Northern Irish business about Northern Irish matters, he should have put Northern Ireland on the face of his amendment. He doth protest too much, Mr Pritchard!

The hon. Gentleman has actually made my case for why these measures are proportionate: they cover the whole of the United Kingdom and it will be down to Ministers in the respective parts of the United Kingdom to decide who they will consult, why they will consult and what areas they will consult on. But as far as England is concerned, I cannot be any clearer: hospitality is out of the scope of our consultation. We will consult on three things: hospitals, schools and play areas.

[Dr Caroline Johnson]

I thank the Minister for giving way, although I would point out that it was not my hon. Friend the Member for Farnham and Bordon’s amendment at all.

[Andrew Gwynne]

But he supported it.

[Dr Johnson]

He is supporting it, but the Minister asked why my hon. Friend did not include things in it. The answer is that he did not write it. The amendments were written by others, one by the Liberal Democrats, and supported by him, which is not the same thing.

The Minister will no doubt have caused concern for the people in hospitality industries in Wales, Northern Ireland and Scotland who are following proceedings today. Could he tell the Committee a bit about the discussions he has had with his counterparts? Have any of them indicated to him their intent regarding hospitality areas in their designated parts of the United Kingdom?

[Andrew Gwynne]

I certainly can. I have had umpteen conversations with Health Ministers from across the United Kingdom, and none of them has indicated to me that they intend to extend this to hospitality. But the point is that, as Ministers in their own legal jurisdictions, it for them to decide who they are going to consult and on what basis they are going to consult. In terms of the powers in this Bill, which areas they want to extend—if any—is a matter for them. It is not a matter for me or for this Parliament.

We are merely legislating to give those Health Ministers the tools; if they wish to go beyond the scope that the English Ministers are setting out, it is their right to do so. That is the devolution settlement. But they will, of course, have the statutory duty to consult, and they will, of course—I would imagine—want to work with businesses, in Northern Ireland, in Wales, or in Scotland, to make sure that whatever measures they bring forward are right and workable, just as we would in the Department of Health and Social Care, should we decide, at some stage in the future, to go further again.

[Dr Johnson]

I doubt whether the Minister has provided a huge amount of reassurance to the hospitality sectors in those jurisdictions.

I want to pick up on a point made by the hon. Member for Cardiff West in his intervention about prisons. As far as I can tell, closed prisons are smoke-free environments—that is already the case both inside and outside—but I understand that prisoners in closed prisons are allowed to vape, including in their cells, where they may be vaping near other prisoners who may not wish them to have that choice. We are depriving people of their liberty for good reason when sending them to prison, but we should not be exposing them to chemical vapour as part of that if they are not vapers themselves.

Could the Minister talk to us about the discussions he has had with Justice Ministers about how provision is made for the public health of those currently in prison?

--- Later in debate ---

[Andrew Gwynne]

I am grateful to the shadow Minister, who is now making my case perfectly for why we need to have the regulations as we do. It may well be that, at some stage in the future, a Public Health Minister, or indeed the Secretary of State, having had conversations with and guidance from the Ministry of Justice, seeks to quickly and simply extend provisions within the prison estate. Were the hon. Lady’s amendments to pass, the ability to do that would not be in the Bill.

We have had conversations with Ministers across Government. This Bill has been subject to the usual write-around, so it has the collective support of the Ministry of Justice. The details of which areas would be in or out of the scope of different measures within the Bill will be a matter for the regulations and for consultation. With that, the shadow Minister has precisely made the case for why having things prescriptively in the Bill ties the hands of Ministers.

[Dr Johnson]

The Minister is suggesting that to be able to restrict access to these products in prisons, he needs to have a wide scope within clause 136. Given that prisons are already smoke-free areas, that surely cannot be the case.

[Andrew Gwynne]

No, but the point the hon. Lady is making is about what conversations Ministers have had with other Ministers to extend the scope, to protect the rights of others and so on. It is precisely for that reason that the Bill is drafted as it is. At some stage in the future, a Government Minister in another Department may well decide that they want to extend the scope, using the powers we are talking about. Under her amendment, we would then have to find a slot in primary legislation to amend a piece of primary legislation. That is precisely why her amendments are unworkable.

The mechanism in place would allow a consultation on an extension; following consultation, secondary legislation would be debated as part of the affirmative process—there would be a debate, a discussion, and a vote in Parliament. That is precisely why the amendments are unworkable, and I call on the Committee to resist them.

I move on to the removal of the test in the Health Act 2006. That is to enable the Secretary of State to more easily make regulations designating outdoor spaces as smoke-free, but only where such a space is a workplace or open to the public. Reinserting the test would conflict with our intention to extend smoke-free status to places I have mentioned—for example, children’s playgrounds probably do not meet the requirement of there being significant risk of significant quantities of smoke. However, making them smoke-free would almost certainly protect some of the most vulnerable.

Since 2006, the evidence base for harms of second-hand smoking has evolved. It is therefore necessary to update the current legislation, as clause 136 does, to provide more flexibility should the Government wish to designate additional smoke-free places in future.

[Dr Johnson]

The Minister is making a reasonable point. However, the evidence can change on what constitutes a significant amount of smoke—in the past, people may have believed that someone had to be smoking in order to come to harm and then that someone could also come to harm in an enclosed indoor environment with someone smoking. It may be that the evidence now shows that even being in proximity to someone smoking outdoors—the fact that you can smell it means you are breathing it in—means you are coming to harm on some level. But does the amendment not account for that with the word “significant”? Amendment 94 says:

“if in the Secretary of State’s opinion there is a significant risk that, without a designation, persons present there would be exposed to significant quantities of smoke.”

A significant quantity of smoke may in the past have been considered to be quite a high volume, but now might be a much lower volume. The flexibility the Minister is seeking is already provided for in the amendment.

[Andrew Gwynne]

The shadow Minister would probably have a large degree of sympathy—at least one of her Back Benchers less so—with our updating the Health Act 2006 to allow us to take action to make more places smoke-free. We think that is right. We now have the ambition to make the whole United Kingdom smoke-free, and this is part of that effort.

--- Later in debate ---

[Dr Johnson]

The Minister is being generous with his time. He knows my thoughts on smoking and vaping, particularly in relation to children, and how important I think creating a smoke-free and nicotine-free generation is—although he does not share the second part. He is talking about how the Secretary of State needs to be able to move with the evidence. I completely and utterly agree with that, but the clause says that there is a significant risk that without designation, persons present will be exposed to significant quantities of smoke.

I support the addition of the smoke-free legislation for spaces like playgrounds. If a playground were to be included, the Secretary of State could quite easily justify that by saying that even seeing someone smoking would encourage children to smoke, particularly if it is their parents, and that therefore it is a sensible action to take.

The words—drafted, I believe by the Minister’s predecessors—are “exposure to significant quantities”. “Exposure” does not necessarily mean breathing it in; children could be seeing it across the playground. “Significant quantities” does not necessarily mean a quantity enough to do them harm. If they cannot see it, they are not being exposed to it and it is not doing them harm, why would we want to stop it happening?

[Andrew Gwynne]

The point is that that is open to interpretation; that now runs counter to our ambition to have a smoke-free United Kingdom. We have put in place a much more flexible and workable measure. The measure from 2006 was right for 2006, but it is not right for 2027, when we hope to introduce the Bill. That is why we are looking to the measures in the Bill rather than the measures as they stood in 2006.

Lastly, I remind the shadow Minister that her amendments apply only to the clause in the Bill that relates to England. If we agreed to them, the powers in England would not be consistent with the powers in the rest of the devolved jurisdictions across the United Kingdom. This is a UK-wide Bill that provides a consistent legislative framework for the whole of the United Kingdom—all four nations—while allowing devolved nations to go further on subsequent regulations if they so wish. For these reasons, I ask hon. Members to withdraw their amendments.

[Dr Chambers]

I think that the official Opposition’s amendment is better, so I beg to ask leave to withdraw the amendment.

Amendment, by leave, withdrawn.

Amendment proposed: 95, in clause 136, page 77, line 12, at end insert—

“The Secretary of State may only make regulations designating external or open spaces as smoke-free in England outside—

(a) an NHS property or hospital building,

(b) a children’s playground, or

(c) a nursery, school, college or higher education premises.”.—(Dr Johnson.)

This amendment restricts the Secretary of State to only being able to designate open or unenclosed spaces outside a hospital, children’s playground, school or nursery.

Question put, That the amendment be made.

Tobacco and Vapes Bill (Twelfth sitting)

Andrew Gwynne Excerpts

Committee stage
Thursday 23rd January 2025 Public Bill Committees

[The Chair]

With this it will be convenient to discuss the following:

Clause 121 stand part.

Government amendment 1.

Clause 122 stand part.

[The Parliamentary Under-Secretary of State for Health and Social Care (Andrew Gwynne)]

It is good to see you back in the Chair, Mr Dowd. These clauses concern the defences and exemptions to the advertising bans on relevant products—tobacco products, herbal smoking products, cigarette papers, vaping products and nicotine products—as set out in clauses 114 to 119, which we have just debated.

Clause 120 sets out three situations in which someone has a defence to the advertising bans. Those are trade adverts, sending information in response to a request and adverts for outside the United Kingdom. The clause sets out that adverts contained only in communications between members of specific, relevant trades in the course of business will have a defence if charged with an offence. For example, a vaping company could send promotional materials to someone responsible for buying products to sell, but that would otherwise be banned if aimed at members of the public. Similarly, a defence exists if the advert is contained in a publication that is not printed or intended to be marketed in the UK. The final defence is that if businesses receive a direct request about their products, they are permitted to respond to that request with material that would legally be considered an advert.

Clause 121 restates existing law that allows specialist tobacconists to advertise specialist products in their shops. Specialist tobacconists will therefore be exempt from the restrictions on advertisements in part 6 of the Bill, provided that their adverts meet certain criteria, such as being visible only inside the shop. The clause empowers the appropriate national authority in each of the devolved Administrations to make regulations to specify what health warnings and information must be included in the adverts. Specialist tobacconists make up a tiny percentage of the market in the UK and are focused on specialist products such as pipes and cigars, and this exemption reflects the specialist nature of the trade carried out by these shops. However, tobacco is a uniquely harmful product, so we will continue to monitor the specialist market closely in case the situation changes.

Clause 122 ensures that no offence is committed under part 6 of the Bill for something that is regulated under the law on displays. For example, displaying a relevant product or the price of the product in accordance with any regulations concerning displays would not be considered an advertisement for the purposes of advertising offences. Without this provision, a display of a relevant product or other material that is permitted may be prohibited as an advertisement. The provision therefore allows for shops to display a vape, subject to the restrictions set out in legislation on their display, without it being considered an advertisement.

However, in the relevant provision for Scotland, the clause refers only to the legislation on the display of the tobacco products themselves and does not include the legislative provision on the display of the prices of the tobacco products. Government amendment 1 has been made to ensure that both are captured when determining whether something is subject to the law relating to displays, as the equivalent provisions do for England, Wales and Northern Ireland. That has been done at the request of the Scottish Government to make the approach in Scotland consistent with that in the other three jurisdictions across the United Kingdom. It is for that reason that the Government commend this amendment and clauses 120 to 122 to the Committee.

[Dr Caroline Johnson (Sleaford and North Hykeham) (Con)]

I noticed that Government amendment 1 was included in this grouping. Does the Minister want to talk about it?

[Andrew Gwynne]

I did.

[Dr Johnson]

Oh, sorry. I must have had a moment.

Clause 120 concerns advertising defences. I wanted to ask specifically about the defence relating to the relevant trade communication being directed solely at persons involved in that trade. Does that include adverts within trade magazines? Does it include trade shows and trade stands where these adverts might be visible? Will these adverts or promotions need to be explicitly directed at trade, and will they need to be only visible to trade, or could this actually create a loophole in which there is a suggestion that these are trade magazines, but are actually more widely available than that and therefore provide an advert to the public? How will that work? What if one is doing a trade show in a relatively public venue such as an exhibition centre?

[Andrew Gwynne]

I can answer that very quickly and clearly, because it was set out in my opening speech. I am not sure whether the shadow Minister was fully paying attention, because it also included Government amendment 1, in relation to bringing Scotland into line with the rest of the United Kingdom on these measures. The legislation sets out that adverts contained only in communications made between members of specific relevant trades in the course of business will have a defence if charged with an offence. I think that is pretty clear.

[Dr Johnson]

I understand what the Minister is saying, but if members of a trade body are being spoken to at a trade show, for example, will the people running the show need to make sure that people who are not members of the trade do not come? Sometimes, people may bring other people along with them. Will there need to be provisions to ensure that when that trade show is advertised, it is not done in a way that promotes the product itself? If the show is to happen, people will need to know about it, so how will they find out? This is just about making sure there are no loopholes.

There is also the business of who is publishing and who is distributing. If someone were to design, produce and print leaflets in the belief that they would be distributed abroad, but then someone gave some young delivery chap, perhaps in his teens, some money to deliver them to a group of households, as happens with pizza delivery adverts and such things, the young lad would be committing an offence of which he may or may not be aware. That is no excuse under the law, of course, but the person with greater culpability would be the person who gave him the leaflet. How does the Minister intend the law to be applied in such a situation?

Clause 121 concerns specialist tobacconists. The Minister has been quite consistent on every aspect of this legislation—apart from penalties—in saying that tobacco in all its forms is bad for people and needs to be eliminated, so I am interested in this specialist tobacco exemption. I understand that the advert is going to be available inside the store, and not visible from the outside, and that it will exclude cigarettes and hand-rolling tobacco. I am interested to understand why it will specifically exclude those and not other forms of tobacco. The Minister might say, “That is what the legislation says at the moment, and we want to keep it the same,” but passing new legislation is an opportunity to change things, review what we currently have and decide whether it needs to be different. I am interested in his reasons for that decision.

The clause defines a “specialist tobacconist” as a shop

“more than half of whose sales…derive from the sale of cigars, snuff, pipe tobacco and smoking accessories.”

That would appear to be on the basis of the cost or value of sales. What is the reason for that definition? It may be that that is the existing definition, but has the Minister considered whether specialist tobacconists should be defined according to whether they sell a greater or a lesser amount of such products? Also, we see vape shops on virtually every high street now, so how will the Bill apply to them?

--- Later in debate ---

[Gregory Stafford]

I completely agree. It is essential that not only this clause and the regulations it will bring in, but all the clauses we have talked about—both those where regulations are included on the face of the Bill and those that give the Minister, the Department for Health and relevant authorities the power to implement other regulations and restrictions—are phased appropriately, so that retailers and manufacturers can adjust to the new laws. They must also be introduced rapidly enough that there are no loopholes, and in the right sequence so that people cannot take advantage of any loopholes.

That brings me to the point that vigilant enforcement and clear guidelines are necessary to prevent such exploitation. I would be interested to know from the Minister whether that links back to the previous clauses, in which we talked about the display of notices.

Likewise, we need to ensure that there is consistency across the jurisdictions. We have devolved government in this country, but if regulations concerning the display and advertisement of tobacco and vape products vary between the different countries of the United Kingdom, there could be cause for some legal issues. It is therefore vital to ensure that clause 122 is applied consistently across all parts of the United Kingdom to prevent confusion among retailers and to maintain the stated aim of the Bill, which is uniform public health standards.

I have a few questions to the Minister. First, will he be developing comprehensive guidelines for what constitutes a display versus an advertisement? These guidelines should include visual examples to assist retailers in understanding and complying with the regulations. I mentioned it before, but regular training and communication is essential so that retailers can be educated about the distinctions and the legal requirements. Continued regular communication will help to address any ambiguities and keep retailers informed about any changes to the laws or regulations that the Minister or his successors might introduce. The Minister is laughing, but I think it is more that he received a funny text than because of my speech.

Finally, robust monitoring and enforcement is essential to ensure that there is compliance with clause 122. That should include routine inspections and clear processes for addressing violations to ensure that the distinction between displays and advertisements is respected. In conclusion, the clause plays a pivotal role in balancing the rights of retailers to display their products with the necessity of restricting advertising that could promote tobacco and vape usage. We on this side of the Committee—mostly—agree with the clause, and I hope that the Minister will answer some of the queries that we have raised.

[Andrew Gwynne]

I thank hon. Members for their questions. The hon. Member for Farnham and Bordon just referred to my smirk, and it was indeed a text from somebody asking whether we should define “clappers” in our guidance as well.

To return to the substance of the Bill, the Government amendment is minor and technical; there was a drafting error, and the Scottish Government have since requested the amendment to correct it and to ensure the regulations and the law, as it appertains to England, Wales and Northern Ireland, will be the same for Scotland.

On the subject of “specialist tobacconists”, let me first make a point of clarification for the shadow Minister and the hon. Member for Farnham and Bordon. We are not saying there is specialist tobacco—there is no such thing. Tobacco is dangerous and uniquely harmful. Tobacco is tobacco. There is nothing specialist about it. A very small number of retailers around the United Kingdom sell niche products; they are specialist tobacconists. That is different to the tobacco being special. There is nothing special about tobacco. The tiny number of retailers that sell things such as pipes and cigars exist in a limited number of places and there are already exemptions in the law for them. As we move towards smoke-free, the reality of market economics means that those specialist tobacconists are not necessarily likely to be around at some stage in the future.

The impact assessment that the Government have provided alongside the Bill makes it very clear. With the measures in the Bill, by 2050—25 years’ time, that is all—we are looking at smoking prevalence in the under-30s being nearly zero. Given that reality, the Government believe that the current exemptions for that small number of retailers will continue. Due to the specialist nature of their trade—they focus on a small number of other tobacco products, such as cigars—they only make up a tiny proportion of the UK market. We know that all tobacco products are harmful, so the Government will, of course, keep a watchful eye on it to make sure that we do not inadvertently grow a new market but, at this stage, we do not believe that will happen.

Specialist tobacconists are not permitted to advertise cigarettes or hand-rolling tobacco because those are the most commonly used types of tobacco. The existing bans on tobacco advertising therefore relate to the sale of those products, whether in specialist tobacconists or the local supermarket, so we are really talking about the advertising exemption for other products. That is a continuation of the existing exemption, which has not caused any issues such as younger people taking up smoking. Any advertising the retailers have cannot be visible from outside the premises. That is really important so that a child walking past one of these random Hogwarts-looking shops that sell a product of which they are hopefully not aware will not ever be attracted to what goes on inside.

[Dr Johnson]

I am pleased that the Minister is considering how shops look from the outside because, when one walks down the high street at the moment, it is not uncommon to find shops where the entire shop window has been turned into a picture of various types of vapes.

[Andrew Gwynne]

Absolutely—I agree with the hon. Lady that how it looks from the outside does matter. That is why, when these exemptions were put into earlier legislation, it was clear that none of the adverts for these niche products could be visible in the shop window from the outside, precisely to protect future generations from ever being enticed to think, “I wonder what a pipe tastes like, or what a cigar is like,” although I am sure the hon. Member for Windsor could, if he chose, give us an hour-long explanation. That is why the legislation is drafted in the way it is. However—and hopefully the industry is listening to this—the Government will, of course, continue to keep an eye on whether this exemption is working in the way that it has previously worked and that we expect it probably will work in the future. If in the future we have evidence that it is not working, the Government can come back and look at it again. However, as things stand, I commend the clauses to the Committee.

Question put and agreed to.

Clause 120 accordingly ordered to stand part of the Bill.

Clause 121 ordered to stand part of the Bill.

Clause 122

Exclusion for advertisements that are displays

--- Later in debate ---

Question proposed, That the clause stand part of the Bill.

[Andrew Gwynne]

The clause provides the Secretary of State with the power to introduce regulations that prohibit or restrict the brand sharing of tobacco products, herbal smoking products, cigarette papers, vaping products or nicotine products. Tobacco brand sharing is already prohibited. Brand sharing, also known as brand stretching, is a form of indirect advertising that promotes the use of a service or product by putting its branding on other products or services, or vice versa. For example, using a tobacco product on a logo or a T-shirt or a confectionery company using its branding on a vape are examples of brand sharing if the intent is to promote vapes. There is a clear association between tobacco advertisements and the uptake of products.

Associating nicotine or vape products with a reputable brand may also incentivise consumers, particularly children, adolescents and other vulnerable groups, to buy the product. We want to stop that happening and to protect young people and future generations from becoming addicted to nicotine. I therefore commend the clause to the Committee.

[Gregory Stafford]

The clause grants the Secretary of State the authority to regulate brand sharing related to tobacco products, vaping products, nicotine products, herbal smoking products and cigarette papers. I think the provision is instrumental in preventing indirect advertising strategies that could undermine the public health efforts in the Bill aimed at reducing consumption of those products.

Brand sharing, in my understanding, refers to the practice of using a brand name, a logo or some kind of distinctive feature associated with a particular product across a range of different product categories. In the context of tobacco and vaping products, brand sharing can manifest in several ways. Cross-product branding uses a tobacco brand’s name or logo on a non-tobacco product such as clothing or accessories to maintain brand visibility despite the advertising restrictions.

On event sponsorships, my hon. Friend the shadow Minister mentioned how we banned the advertising of tobacco products at Formula 1, the cricket and so on. Associating a tobacco or vape brand with events indirectly promotes the brand to a broader audience. Merchandising—the selling or distributing of merchandise bearing the branding of tobacco or vape products—can appeal to various demographics, especially young people.

[Gregory Stafford]

I do not want to put words into the Minister’s mouth; I am sure he can respond to my hon. Friend when he gets up. I think there has been relative unanimity on the Committee. Unlike alcohol and gambling, to use the two examples that my hon. Friend gave, tobacco is significantly more dangerous. Whereas there are safe levels of indulgence in gambling and alcohol, there is no safe indulgence in tobacco products. I think the Minister has made that very clear. If I have misinterpreted what he said, I am sure he will correct me.

The rationale for the clause is important: it closes advertising loopholes. Traditional advertising channels for tobacco products have been progressively restricted to reduce their appeal and accessibility, especially to young people. However, brand sharing could present a loophole that companies could exploit to continue to promote their products indirectly. By regulating brand sharing, the clause aims to close that gap, ensuring the intent of the advertising restrictions, which we have previously discussed, is fully realised.

Secondly, as with measures throughout the Bill, the clause aims to protect public health. Indirect advertising through brand sharing can subtly influence consumer behaviour, particularly among impressionable groups such as adolescents. Exposure to branding on non-tobacco products or at events can normalise tobacco and vape use, potentially leading to their initiation and then continued usage. Regulating brand sharing is therefore a critical step in protecting public health by limiting the avenues through which these products are promoted.

Once again, the clause brings us into line with a number of international standards. Many countries have already recognised the risks associated with brand sharing and have implemented regulations to address it. For example, the World Health Organisation’s framework convention on tobacco control, which I previously mentioned, recommends comprehensive bans on all forms of tobacco advertising, promotion and sponsorship, including indirect forms such as brand sharing. By empowering the Secretary of State to regulate brand sharing, the UK is aligning itself with international best practices in tobacco control.

However, there are some challenges and considerations. The first is defining the scope of brand sharing. One of the primary challenges I see in regulating brand sharing is establishing clear definitions and boundaries. Determining what constitutes brand sharing requires careful consideration to avoid an ambiguity that could be exploited. I hope the Minister will give us some understanding of what the guidelines and boundaries might look like. Clear guidelines are essential to ensure that both regulators and businesses understand the limitations and comply accordingly.

The definition of brand sharing in subsection (2) involves broad and somewhat ambiguous terms, such as

“anything which is the same as, or similar to, a name, emblem, or any other feature”.

The use of such open-ended language could create uncertainty about what constitutes a violation of the regulations. How precise must the similarities between a relevant product and another service product be in order to be considered brand sharing? It would be helpful if the Minister could help us understand that.

There is also then the balancing of the regulation with commercial rights, which I think my hon. Friend the Member for Windsor alluded to earlier. While the object is clearly to protect public health, it is also important to consider the commercial rights of businesses. Over-restrictive regulation could have unintended economic consequences, particularly, again, for small businesses involved in merchandising or event sponsorship. I have said this before: if the product is legal to consume, we must ensure that whatever regulations we apply are equal and fair for both a large retailer or manufacturer and a small retailer or manufacturer. The regulation is either highly restrictive or highly permissive, but it must be the same. A balanced approach is necessary to achieve the public health goals without imposing undue burdens on legitimate commercial activities.

As I have said before in debates on other clauses, enforcement and compliance potentially bring some logistical challenges. The monitoring of so many various channels, including events and merchandise digital platforms, requires substantial resource. Ensuring compliance among diverse industries and settings necessitates a co-ordinated effort between regulatory bodies, industry stakeholders and the public.

In addition to the questions I have already asked, could the Minister tell us what will be in the accompanying comprehensive guidelines? I urge the Minister to collaborate with public health experts, industry representatives and legal advisers to formulate clear and detailed guidelines on what constitutes prohibited brand-sharing practices. Those guidelines should be regularly updated to address any emerging trends and technologies, which we have discussed previously.

Stakeholder engagement is entirely appropriate and important. That includes with businesses and consumer groups, because we need to understand the regulations and encourage, where possible, voluntary compliance rather than compliance through enforcement operations. Educational campaigns can help stakeholders recognise the public health rationale behind regulations.

Finally, to go back to what I said about having robust monitoring mechanisms, we need to establish some kind of body to oversee and monitor to ensure compliance. Using technology and public reporting mechanisms can aid in identifying the violations and taking prompt action.

In conclusion, I support the intentions of the clause, but the ambiguity around what exactly constitutes brand sharing is something I would like to hear about from the Minister. Potentially, some challenges in enforcement are posed if the clause and the Bill become law.

[Andrew Gwynne]

I am grateful to the hon. Gentleman for his thoughtful contribution and questions. First, to be clear, we are aligning with the same regulatory framework that was used for tobacco. Tobacco brand sharing was done via regulations following the introduction of TAPA—the Tobacco Advertising and Promotion Act 2002—and the necessary consultation through that process. We will of course consider brand-sharing restrictions for vapes once the Bill has received Royal Assent.

It is also important to say that following the ban on direct advertising, we will consider whether further regulation of brand sharing is needed at that point. If it is deemed necessary, we will need to assess the scope and the impact of any regulations to ensure that they are proportionate—precisely the point that the hon. Member for Farnham and Bordon was setting out. My belief is therefore that it is more appropriate to regulate brand sharing via secondary legislation following consultation, not only to get that proportionate balance, but to ensure that any regulations are well understood, workable and enforceable.

An added issue is that advertising is devolved to Scotland and Northern Ireland—but not to Wales—so the Secretary of State must obtain consent from Scottish Ministers and the Department of Health in Northern Ireland before making any regulations containing provisions that would be within the legislative competence of the Scottish Parliament and the Northern Ireland Executive. We want to have the measures in place across the United Kingdom—so that there is no loophole, with brand sharing north of the border but not south of it, for example—so it is important that we go through the correct procedures to ensure that my counterparts in Scotland and in Northern Ireland are fully content with the direction of travel that we may wish for when it comes to England and Wales, which is the responsibility of the Secretary of State in the UK Government.

Question put and agreed to.

Clause 123 accordingly ordered to stand part of the Bill.

Clause 124

Sponsorship: tobacco products

Question proposed, That the clause stand part of the Bill.

[The Chair]

With this it will be convenient to consider clause 125 stand part.

--- Later in debate ---

[Sarah Bool]

That is a possibility. It always depends on the terms of the contract itself, but in theory they could agree a 10 or 15-year contract and sponsorship deal. It is interesting that this could be one of the overhangs that we see, so we have to be aware of it going forward.

[Andrew Gwynne]

The clauses make it an offence for a person to be involved with a sponsorship agreement where the purpose is to promote in the course of business tobacco products, herbal smoking products, cigarette papers, vaping products or nicotine products. Anyone convicted of an offence under the provisions may be subject to imprisonment, a fine, or both. Tobacco sponsorship is currently banned under the Tobacco Advertising and Promotion Act 2002. There is a long-standing, well-established relationship between tobacco advertising and tobacco consumption.

Clause 124 restates the current position for a person involved in the sponsorship of a tobacco product. We are consolidating existing tobacco legislation in the Bill to provide a coherent narrative for readers, rather than have it spread over lots of different pieces of legislation. A large part of the Bill brings the legislation into one place, so that from Royal Assent onwards, the go-to place for anybody with any questions about tobacco control will be this piece of legislation, rather than it being dispersed across different Acts of Parliament.

Tobacco sponsorship is already banned, but importantly, the Bill expands the offence to include herbal smoking products, cigarette papers, vaping and nicotine products. The restriction will mean that vaping and other nicotine product companies will, for example, not be permitted to sponsor sports teams, which is something that we have seen in recent years. It might upset the hon. Member for Windsor, but I have to say that not a single child should ever be able to look up at their favourite sports stars—people who should be role models—and see them covered in branding for products that are harmful and addictive. That is the point here.

[Dr Johnson]

Would the Minister like to comment on whether many of the athletes may feel uncomfortable wearing shirts with such branding on?

[Andrew Gwynne]

I am sure that many do. That is another important aspect.

[Dr Danny Chambers (Winchester) (LD)]

To reinforce the point that athletes may be uncomfortable wearing that type of branding, they are not only role models for children, but the epitome of health, fitness and what the human body can achieve. It seems outrageous that they should be advertising harmful products.

[Andrew Gwynne]

Well, some of them are—the way Man City have been playing this season, I am not quite sure. Anyway, we will get back on to the Bill as quickly as possible.

The ban will apply to agreements entered into after the clause comes into force, two months after Royal Assent. It will be an offence if a contribution is made from either party after the specified date, which will be set out in future regulations. The ban will apply to any agreements entered into after that date, and will therefore not apply to existing contracts. The reason for the two-month period is to provide businesses with advance warning and to prevent them from entering into new agreements.

The hon. Member for South Northamptonshire asked whether this could create a rush to get sponsorship deals in place within that two-month window. That is a fair question, but I think that is unlikely for a number of reasons. First, sponsorship deals are pretty tricky contracts and it tends to take more than two months to reach contractual agreement. Secondly, even if matters were expedited, most clubs already have their deals in place, and they would not replace something when they already have a contractual arrangement for something else. Were that unlikely scenario to play out, we would be looking at only a small number of cases anyway.

When drawing up the regulations, we will have to be careful to ensure that no new contract can be signed, and certainly not for the kind of time period that the shadow Minister set out. That would be really out of the spirit of this legislation and the Government might have to come back to tighten it up further.

[Dr Johnson]

I have a couple of questions about the rush of people trying to get contracts. First, presumably such a contract would not need to start straight away, so one could enter into a sponsorship agreement for some future period. As the Minister said, the sponsorship agreements are done for this season and being negotiated for the next, but presumably that would not stop a business entering into a contract to provide sponsorship for the next season, or even the season after. When the Government brought in VAT on private school fees—I should declare an interest here—they put in a forestalling measure that prevented anyone from entering into a contract to pay them ahead from, I believe, 28 July last year. They seem to be taking a much more lenient approach to the advertisers and sponsors of vaping and nicotine products than they are to parents wishing to pay for their children’s education.

[Andrew Gwynne]

The hon. Lady raises an interesting point; I will take that away and look at it. Perhaps with the exception of the hon. Member for Windsor, everyone on the Committee agrees that we do not want our footballers, rugby stars or athletes to be emblazoned with adverts for vaping products, so the more we can do to tighten up the legislation further, the better.

I will just politely correct the hon. Member for Windsor that the term for someone from the historic County Palatine—including yourself, Mr Dowd—is a Lancastrian. My late father was the Lancashire cricket correspondent, first for Cricket Call, which was a BT paid-for service, and then for BBC North West. He was there in 1990 when Lancashire won both the NatWest and Benson & Hedges cup finals—the double at Lord’s. I still have copies of my late father’s book, “Double Delight”. I would say that they are available at all good booksellers, but they are available from me if the hon. Gentleman wants one.

The hon. Member for Windsor made an important point. I had just come out of secondary school in 1990, which shows how long ago it was, but it was pretty commonplace for tobacco companies to advertise at major sporting events like Lancashire cricket matches and others. The fact is that that was a long time ago, and things have changed for the better. The Benson & Hedges cup final, in cricket of all games, is a thing of the past. Hopefully, at some stage in the near future, we will look back at vape sponsorship of football clubs as a thing of the past, because that is where it deserves to be.

[Sarah Bool]

This is just off the top of my head, but on a technical point about clause 125(1), in terms of vape sponsorship, a person will be guilty of an offence only after the provision comes into force. I appreciate that there is the two months, but they also have the window of time while the Bill goes through Parliament, so they potentially have a couple more months for that.

I do wonder about how this is going to work in practice, because, in theory, a company that is offering sponsorship—if they enter into that agreement now—will not be in trouble for the next couple of years for doing that, yet under preceding clauses anyone who designed or printed material for any of those sponsorship deals would be guilty of an offence. We suddenly have a position where, potentially, the sponsors themselves are not guilty of an offence while the actual designers, and those who are publishing the sponsorship material, are. That is an interesting nuance.

[Andrew Gwynne]

The hon. Lady makes a really important point. When we look at things in isolation, as we tend to do with these clauses, we look at them through a narrow prism, but this Bill contains a wide range of powers and legal responsibilities that will help to make things like those sponsorship deals incredibly difficult before the legislation is in force. It is very clear that, after Royal Assent, the requirements that the hon. Lady rightly sets out in terms of advertising, printing, publishing and so on will apply, and separately there will be this two-month window that we are giving, but the whole of the law needs to be read together. Hopefully that gives some assurances on why we believe that these measures, taken in the round, are as robust as they can be.

[Mr Barros-Curtis]

I am grateful that the Minister will take away the point raised by the hon. Member for South Northamptonshire, discuss it with officials and come back to us. When doing so, it will be worth reflecting on the fact that, as the hon. Lady knows from her previous work, a lot of commercial contracts tend to have force majeure clauses, which may well envisage legislative changes in countries relevant to the jurisdiction of the contract that could impact the commercial value of that contract. This may not be as big a problem as some fear, but it is something to be looked at as part of this work. Of course, given that the average wealth of a Premier League club is £1.2 billion, I am sure they would survive such a clause being activated in those examples.

[Andrew Gwynne]

My hon. Friend makes a very good point. I am grateful that we have somebody from the legal profession on this Committee to advise this Minister, who is not a lawyer, on provisions that may well be put into any kind of contractual discussion that may be starting now, and to alert the parties to such a contract that the law in the four jurisdictions of the United Kingdom is changing and will therefore affect any agreements that are being put into place in advance of that legislation coming in. That is an important point.

[Mr Barros-Curtis]

There is one further point that I wish to make. The hon. Member for South Northamptonshire and the shadow Minister were talking about the display of logos or company names on football shirts as an example of the practicalities of enforcement. Would my hon. Friend like to comment on the fact that, in European games, when teams that are sponsored by, for example, an alcoholic beverage or gambling company are playing countries where that is prohibited, the shirts of the relevant football team tend to have black tape over the logos, to prevent them from being displayed in the ground and on TV across the world.

[Andrew Gwynne]

My hon. Friend, as well as being a sound lawyer, is a sound mind reader, because that was precisely my next point. Rightly, Members are testing the legislation. The purpose of this Committee is to tease out how we expect the legislation to work. When it comes to sporting events, from time to time there will be English, Welsh, Scottish and Northern Irish teams playing in other countries, and more importantly teams from other countries playing within the United Kingdom. My hon. Friend rightly points to the existing practice that where something is illegal, those images are covered up.

[Gregory Stafford]

I am going to test the Minister’s legal knowledge now—perhaps his hon. Friend the Member for Cardiff West or one of his officials can come in and save him. Is the Minister saying that when that happens in other countries, it is due to a legal requirement? I understood that it was to be culturally sensitive to the nation we were playing in, rather than there being a legal requirement—for example, covering up alcoholic drinks in a country that does not approve of alcoholic drinks. Conversely, in the Bill and in the regulations, is there something that says that those sponsorships, which would be vapes or tobacco in this country, would require some sort of covering up or a change to a kit with vapes advertised on it if a country were playing here?

[Andrew Gwynne]

I am grateful to the hon. Member for that question. The answer is going to be the stock answer that I have given throughout—that much of this detail will be down to how we draft the regulations and so on. The law of the United Kingdom and its four respective jurisdictions of England, Wales, Scotland and Northern Ireland is the law of the land. This Parliament, in passing this legislation, expects the law of the land to be adhered to. If the law of the land is not adhered to, there are strong enforcement measures and penalties for those not applying the law as passed by Parliament.

Going back to existing contracts, it is really important to emphasise the legal advice that the Government received in the drafting of the Bill: that we need to be proportionate and pragmatic and we cannot retrospectively legislate to stop existing contracts. It is really important that we avoid retrospectivity in the design of the clauses in front of us, because the principle that underpins our legal system is that the law is prospective, not retrospective.

[Mr Barros-Curtis]

I appreciate that, and I completely agree. Learned colleagues and others with legal training will probably remember the auspices of what Parliament can and cannot do. I appreciate that this is something the Minister will have to take away but, while fully agreeing that Parliament cannot be retrospective in the legislation it passes, is it not the case with commercial contracts that there will typically be a requirement for the parties to adhere to the laws that apply to the jurisdiction and to the parties themselves?

Of course, those laws can change in the future. It is not that it is a day one obligation at the time the contract is entered into and then is never checked again. It has to be an ongoing obligation. While I fully understand the point and agree with what the Minister is saying, can he take away that point about the ongoing obligation and the advice? That way, people who have these types of contracts can rely on knowing whether they are or are not in breach of the Act—if, as we all hope, the Bill gets Royal Assent and becomes an Act.

[Andrew Gwynne]

My hon. Friend sets out a really important point. I am happy to take that away for officials to look at. We want to ensure that companies that currently sponsor sports kits are no longer able to do so, and that sports clubs that have entered into such contracts are not allowed to extend them beyond the dates of their current existence. His brain is much more legalistic than mine, and we do not want the intention behind the law to be circumvented using legal routes that the best lawyers in the land will probably use to try to find a way around it. I will ask my officials to look at that in more detail, because it is a really important point. I hope he accepts that response.

[Dr Johnson]

I understand the point that the hon. Member for Cardiff West is trying to make about a standard clause being that if a contract breaches the law, the contract falls. In clause 125, however, the Minister appears to be giving a company that promotes vapes by sponsorship an opportunity to enter into a contract, before the legislation comes into force, that would be legal afterwards.

[Andrew Gwynne]

The shadow Minister is right. There will be a narrow window in which that will be possible—[Interruption.] She asks why, and it is because once the Bill receives Royal Assent, it will bring in a two-month window. That is how the law is shaped, to give us the scope to get these measures right and ensure that we make the framework as watertight as my hon. Friend the Member for Cardiff West wants. We believe that that is the proportionate way forward. We cannot make retrospective decisions; if contractual arrangements are under way at Royal Assent, an immediate cut-off could leave the Government open to challenge.

[Sarah Bool]

I understand that two-month period, but does it also apply to the earlier provisions on the creation of offences relating to publication? If we had some alignment there, neither party could potentially be in breach. That is merely a technical point, however.

The other point—perhaps for when the Minister goes back to the Department—is about force majeure, which the hon. Member for Cardiff West mentioned and which I would like more investigation into. Force majeure concerns acts of God, or something unexpected. I think lawyers would argue that a Government Bill was expected and foreseen, so there would have to be some other form of break clause or right. This debate is getting far too technical for this forum, but it is perhaps something that the Minister can take away.

[Andrew Gwynne]

As I said to my hon. Friend the Member for Cardiff West, we will take all this away and look at it in detail, and we will come back to Members. I am just about legally savvy enough to understand the point that the hon. Lady is making that a break clause or something like it would probably be required, because the coming into law of the Tobacco and Vapes Bill on Royal Assent is expected—it is not an act of God, and it will not come as a complete shock and surprise.

Finally, clause 133 allows us to extend all of part 6 to cover devices that enable a

“tobacco product to be consumed”

or

“an item which is intended to form part of such a device”,

but that are not in the Bill.

[Sadik Al-Hassan (North Somerset) (Lab)]

On the conversation we were having previously, does the reference in clause 125(3) to a “specified date” mean that we can have an open discussion with the Secretary of State in the next stage of the Bill’s passage about deciding at what point the provision will apply to the contracts?

[Andrew Gwynne]

I will take that away, because I do not know the answer off the top of my head. In bringing forward regulations, the Secretary of State and I will want to ensure that we get these measures right. That is why there are statutory duties to consult on secondary legislation throughout the Bill. That will ensure that we get these measures and the details right, and that there will hopefully be no ambiguity about the different dates for the offences of printing, publishing and distributing advertisements or about those related to sponsorship deals and the production of the kits that come out of them. With that, I commend the clauses to the Committee.

Question put and agreed to.

Clause 124 accordingly ordered to stand part of the Bill.

Clause 125 ordered to stand part of the Bill.

Ordered, That further consideration be now adjourned. —(Taiwo Owatemi.)

Tobacco and Vapes Bill (Eleventh sitting)

Andrew Gwynne Excerpts

Committee stage
Thursday 23rd January 2025 Public Bill Committees

[Dr Johnson]

Clause 100 concerns product safety, which is important. Even when a product is not safe, it should still be as safe as it can be and should contain only those things that are expected. When Lincolnshire police took a sample of vape devices from children from a school in my constituency, they found that many of the vapes contained dangerous ingredients that should not have been in there, including, in one case, I believe, an ingredient banned in the UK for many decades.

Clause 100 is important: the Minister must ensure that items on the market are safe. I come back to the evidence from Dr Laura Squire from the MHRA. She said that licensing a medical product does not mean that it is safe, and that these vapes are not medical products either. I am grateful to the Minister for saying in the last session that he is looking for a new home for the licensing and registration process for vapes and vaping products, because “MHRA-registered” suggests to the consumer that those things are in some way safer and more fully tested than they have been.

Clause 100 suggests very sensible regulation, but it gives the Minister the power to do that without significant oversight, even though the affirmative procedure applies. Since clause 90, all the Bill has done is to confer powers on the Secretary of State to regulate without actually providing a huge amount of detail on the Secretary of State’s intent. One never knows what the intent of a future Secretary of State could be in this regard.

Will the Minister comment on why regulation will be in secondary legislation rather than being detailed in the Bill? I understand the need to be agile and to think quickly to try to stay ahead of an industry that will try to adapt to addict more people to nicotine in other forms, but it would have been possible for the Minister to put much of that detail in the Bill, and to have taken a power in a final clause to amend parts of those regulations by statutory instrument. Most of the intent and most of the regulation would then have been known very quickly, but could be altered and adapted later. Why has the Minister taken the approach that he has, rather than a more up-front approach?

Clause 100(1)(a) requires

“producers or importers to have processes in place”.

Again, this is an important point. Most of these products seem to be made overseas, where of course the UK courts do not have jurisdiction. It is at the point of import, and with regards to the person who is importing, that we may need to be more responsible than with a producer where the items are made overseas.

I also urge the Minister, echoing the point made by my hon. Friend the Member for Farnham and Bordon, to consider online sales. We see already that some regulations that are in place for the real world rather than the virtual world create loopholes for regulations to be circumvented. Clearly, public safety has to be the Government’s first priority. The testing in clause 99 and the product safety regulations in clause 100 are a welcome initiative, but clearly the devil will be in the detail and the detail is not available to us today.

[The Parliamentary Under-Secretary of State for Health and Social Care (Andrew Gwynne)]

I am sorry that your croakiness is getting the better of you, Sir Roger, but hopefully you will be on fine form tomorrow for the private Member’s Bills—I am not sure whether the Whips on either side of the House are praying for that.

On clauses 99 and 100, I will go through the questions posed by the shadow Minister and the hon. Member for Farnham and Bordon. It is the responsibility of trading standards to test products if they believe a product contains illegal substances or could contain too much nicotine. Trading standards currently test products on an ad-hoc basis, which is contingent on funding. We aim to establish a testing regime to regularly check that products on the shelves are what they say they are. That will support overall enforcement, will ensure that registered products are safe for consumers and will allow retailers, in both brick-and-mortar establishments and online, to have greater clarity about and confidence in the products that they are able to stock to sale.

It is really important to consider online sales as a growing area. These measures have to be taken within the wider context of clauses and measures that we have already debated, in that any product for sale in the United Kingdom, whether in a shop or online, will have to be registered, and any retailer, whether a shop or online, will have to have the appropriate licences in place. There are clear and substantial penalties for breaching those licensing arrangements, and there are real and substantial consequences for selling products that are not in accordance with the descriptions on the registration of those products. When all of that is put into context, and testing is added in, we believe that this will be a robust regime.

--- Later in debate ---

[Dr Johnson]

Clauses 101 and 102 deal with the treatment of, and matters dealt with by, the 2016 tobacco regulations. Again, they provide the Secretary of State with powers to make regulations. Whether or not that will be done well, we are not really sure at this stage.

I understand the point the Minister made in response to the last debate, and it is of course true that regulations can be different in each part of the United Kingdom. In his discussions with Ministers in Wales, Scotland and Northern Ireland, they may have wished to proceed with regulations after the Bill, rather than to put them on the face of the Bill. However, that does not explain why the Minister has chosen to do the same, and I would be grateful if he could explain his choice to make regulations after the Bill, rather than to put them on the face of the Bill, with the power to modify. I ask particularly because we are now into, I think, the 12th consecutive clause that provides powers to regulate and that offers detail only on what any regulations might or might not say, rather than necessarily on what they will say.

In that vein, clause 101 outlines provisions to allow the Secretary of State to make regulations similar to, or corresponding with, the Tobacco and Related Products Regulations 2016. That is to be done under a new regulatory framework, which would seem to be designed to cover gaps that may exist in the powers under those regulations. Subsection (1) says:

“The Secretary of State may by regulations make provision…that is similar to or that corresponds to any provision of the Tobacco and Related Products Regulations 2016…other than Part 7 of those Regulations”.

Part 7 of those regulations deals with electronic cigarette advertising. The Minister may feel that later parts of the Bill will deal adequately with this point, but I would be grateful if he could explain why that part has been taken out. That is not instinctive, because other aspects of those regulations could be too. What is the reason for excluding that part? Otherwise, I have no particular points to make about clauses 101 and 102.

[Andrew Gwynne]

Clause 101 allows the Secretary of State to make regulations similar to any provisions set out in the Tobacco and Related Products Regulations 2016 —the TRPR, which we discussed in our debate on the earlier clauses—thereby amending them if needed.

In 2016, the TRPR implemented the 2014 EU tobacco products directive. The TRPR deals with the manufacture, presentation and sale of tobacco and related products, including herbal products for smoking, nicotine, vapes and refill containers, as well as smokeless and novel tobacco products. However, it does not regulate all products. As we know, new nicotine products such as nicotine pouches have emerged on the market—we discussed such things in our earlier deliberations—and we currently have no powers to change the regulations. We are also limited in what we can do within the existing powers—for example, on vape packaging.

The Bill builds on the TRPR and allows us to go much further, with new powers on, for instance, packaging and flavour requirements, and new registration powers that could be extended to non-nicotine vapes, nicotine pouches, heated tobacco devices and cigarette papers. As we have ascertained, the tobacco and vaping industries are extremely innovative and have previously attempted to circumvent regulations and exploit loopholes. The clause helps to stop them doing that by allowing us to amend the TRPR if necessary.

Clause 102 enables regulations to be made under powers in part 5 of the Bill to amend provisions in the Tobacco and Related Products Regulations that are within scope of those powers. This is a technical provision because, as I said in the previous debate, we have limited powers to amend the TRPR. For instance, if we introduce new vape packaging requirements using powers in the Bill, the clause will allow us to amend the TRPR if necessary, so that the new packaging requirements fit with those imposed under the TRPR.

The shadow Minister raised issues relating to secondary legislation. The technical and detailed nature of many of the Bill’s requirements means that they are not suitable to be put on the face of the Bill. For example, we may need to amend those requirements in response to market changes. It is also necessary to include detail on the circumstances of when products must be recalled, which will change over time.

There is a broader point here: with all the regulations that we propose to bring before Parliament, we want to get the measures right. We have a statutory duty in the Bill to consult before bringing in regulations, which is in part why we are making the measures in the way that we are. Part 7 of the TRPR is excluded because those things will now be in part 6 of the Bill. I commend the clauses to the Committee.

Question put and agreed to.

Clause 101 accordingly ordered to stand part of the Bill.

Clauses 102 to 104 ordered to stand part of the Bill.

Clause 105

Sub-delegation

Question proposed, That the clause stand part of the Bill.

[The Chair]

With this it will be convenient to discuss clauses 106 to 111 stand part.

[Dr Johnson]

Clause 105 states:

“Regulations under this Part may confer discretions.”

I confess that I do not understand what that means. I would be grateful for the Minister’s explanation.

Clause 106 is about the power to make provision binding on the Crown, which we have discussed at some length. My only point is on subsection (4), which clarifies that public servants are still accountable under the regulations. Some may have concerns about the enforcement of regulations within Government bodies. Could the Minister say anything further on that?

Clause 107 gives the Secretary of State power to make amendments to this legislation through regulations. It is quite a broad and flexible position: the Government can remove outdated laws that are inconsistent with new regulations established under the Bill and ensure that the regulatory framework can evolve. To some extent, that makes sense. Again, the Government seem to be keen to ensure that they can stay one step ahead of a very adaptable industry and try to protect the country from nicotine addiction. However, the clause is quite broad. I would be grateful if the Minister could further elaborate on his intent in it.

Clause 108 provides for the consequential removal of section 94 of the Children and Families Act 2014 because it is no longer needed. Clause 109 is about enforcement.

Clause 110 is about the consultation process. The requirement to consult before making regulations promotes transparency and accountability in the decision-making process and allows for adjustments and feedback from various groups, in the same way that line-by-line scrutiny of the Bill allows adjustment in line with discussion. It ensures that regulations are fair and based on a broad range of insights and evidence. However, I would be keen for the consultation not to be so long as to delay bringing in the regulations. As I have said before, much of the Bill hinges on the regulations the Government can provide. If the consultation processes are very long and drawn out, it could be a long time before any of these measures come into force to protect our children, in particular.

[Andrew Gwynne]

Sub-delegation allows functions to be carried out by someone who is not named in the primary legislation. We believe that that is vital for flexible implementation of Government policy and to keep the wheels of Government turning. Sub-delegation is a long-accepted part of the legislative process, and having the ability to allow technical experts to undertake technical tasks, or to set out very detailed technical criteria in guidance instead of using parliamentary resource, will allow us to get on with implementing the measures in part 5 of the Bill.

The shadow Minister is right to be concerned about having safeguards to ensure that any sub-delegation of authority is not abused. Sub-delegation to persons must be set out in regulations. As I have previously said, there is also a statutory duty to consult on any regulations made under part 5. The regulations will be subject to the affirmative procedure, meaning that Parliament will have an opportunity to consider any sub-delegation before the regulations take legal effect.

On the wider consultation the shadow Minister referred to, the Government chose to include consultation clauses because we want valuable input from different stakeholders on our proposals before they are introduced. As is conventional with such clauses in primary legislation, the clause does not prescribe the specific people the Secretary of State must consult. That is to ensure that the Government can consult appropriate stakeholders, and the list may evolve over time.

UK-wide regulations made under part 5 might deal with devolved matters. The UK Government are therefore required to seek consent from the devolved Governments. My Department will continue to work closely with the devolved Governments on proposals for UK-wide regulation of products. I therefore commend the clauses to the Committee.

Question put and agreed to.

Clause 105 accordingly ordered to stand part of the Bill.

Clauses 106 to 113 ordered to stand part of the Bill.

Clause 114

Publishing advertisements

[Dr Johnson]

I beg to move amendment 87, in clause 114, page 63, line 16, after “product,” insert

“except for the public health purpose of promoting vaping as a cessation tool for existing tobacco smokers,”.

This amendment would allow vapes to be promoted as a quit-aid/public health measure.

--- Later in debate ---

[Jack Rankin]

I am going to make some progress. Even judging by the Government’s own standards, we should be treating vaped tobacco and heated tobacco very differently from cigarettes. We should be a little careful about the unintended consequences of this measure, and I hope the Minister can say how he might consult other bodies to look at those unintended consequences.

I have a small concern with the internet services measure in clause 119. Again, it seems that the Government’s aims in this legislation is to prevent targeted communication on vapes and nicotine products to adult smokers, such as via emails or digital channels, which can reach them directly. I understand the point about not wanting to aim such communication at children, but targeted communication, such as using people’s internet search history, could be an effective means of encouraging smokers to quit. I mentioned a few weeks ago the work that NHS Essex is doing with a vaping company, targeted at adult smokers. I do not think the Government, in achieving their aims of a smoke-free generation, should be too prescriptive on this.

[Andrew Gwynne]

I am grateful to hon. Members for our discussion on amendment 87 and subsequent clauses. These amendments intend to make an exemption under the advertisement ban to allow vaping products to be promoted by businesses as a smoking cessation tool for existing tobacco smokers. I am sympathetic to the shadow Minister’s intention behind the amendment to ensure that smokers are encouraged to use vapes as a quit aid. That is why the Bill as drafted will continue to support the promotion of vaping as a quit aid for smokers through the appropriate channels. By “appropriate channels”, I say to the hon. Lady that we mean public health authorities.

[Dr Johnson]

I want to clarify one small point, if I have not made myself completely clear. On a personal level, I do not particularly want people to be persuaded to go from smoking to vaping, because I think it is an alternative addiction that they will get stuck on. I would much prefer them to be directed towards other forms of nicotine replacement therapy, which will be effective and more short lived. However, given that the current medical advice is that vaping is better, I think it is important that it is available.

[Andrew Gwynne]

I get that the shadow Minister is dancing on a pinhead, but she has brought to the Committee a set of amendments for which that would be the purpose. If they are pushed to a vote, I am sure we will have the bewilderment of the shadow Minister yet again abstaining on measures that the shadow Minister has brought before the Committee.

We believe it is for public health authorities to promote vaping as a quit aid for current smokers. For example, local stop smoking services will continue to be able to promote vapes to smokers as a less harmful alternative following the passage of the Bill. We strongly believe that any promotion of vaping as a way to quit smoking is best led and delivered by the appropriate authorities, such as local stop smoking services, public health professionals and the national health service.

The clauses in part 6 of the Bill, taken in totality, will form a complete ban on advertising and sponsorship for tobacco products, herbal smoking products, cigarette papers, vaping products and nicotine products, bringing them all in line with tobacco. It is unacceptable that children are exposed to vape adverts on the sides of buses and in shop windows when they make their way to school.

Clauses 114 to 117 make it an offence for anyone

“acting in the course of business”

to publish, design, print or distribute an advertisement

“whose purpose or effect is to promote”

a relevant product within the Bill. Upon conviction, anyone who has committed an offence under part 6 will be liable to a fine, imprisonment or both. These clauses are an essential part of the overall suite of restrictions that will ban advertising of relevant products within the UK. Taken together they will ensure that even if someone has not designed or published an advert, it will still be an offence to print or distribute that advert. This is key to stopping their eventual distribution. I hope that answers the questions about whether there is a loophole allowing adverts produced for international markets to be distributed in the United Kingdom. The distribution of those adverts will be an offence.

Clause 118 makes it an offence to cause the offences I have just set out. It would be an offence if a person “knows or has reason to suspect” that they are causing these things, whereas if someone unknowingly delivered a package containing leaflets, they would not be guilty of the offence. Without this clause, it would be possible to instruct others to publish, design, print or distribute adverts without committing an offence. Clearly, we need to ensure that it is also an offence to cause these things to happen.

Lastly, clause 119 makes it an offence to provide an internet service in the course of a business by means of which an advert for a relevant product is published or distributed. This would mean that an organisation that provides a service to a person—for example, Sky or TalkTalk—would commit an offence if they provided a service that enabled the online advertisements to happen and if they permitted that space to be used to promote relevant products. That could include becoming aware that the service is hosting a vape advert and subsequently failing to take that advert down. This is particularly important, as young people, and some not-so-young—we now know that, if we have a hoof that needs trimming, the hon. Member for Farnham and Bordon is our man, although I am not sure whether he provides the service or just passes the request on—

[Gregory Stafford]

Things haven’t got that bad yet.

[Andrew Gwynne]

Clause 119 is important, as children spend a lot of time online and therefore are more exposed to a variety of internet services. It is unacceptable that a child using the internet to study might be exposed to a variety of vape adverts. We need to take action to stop these products being deliberately advertised to children, to protect future generations from becoming hooked on nicotine.

The shadow Minister’s amendments would in theory allow any shops or businesses to advertise vaping products to existing tobacco smokers. It would be incredibly difficult to target the advertisement of vaping products to current smokers alone, without the risk of children and non-smokers seeing the promotional material. That would not only make enforcement complicated, but make the messaging about the ban inconsistent. Research on tobacco advertising bans has shown that comprehensive bans were significantly more effective than partial restrictions in reducing smoking rates.

Hon. Members has posed a number of questions, which I will address. What constitutes an advert and how will the decisions be made? The Advertising Standards Authority is the regulator, and it will take a proportionate approach. All adverts are captured. Decisions on whether something is an advert will be made on a case-by-case basis, and it is for the ASA to decide. If the purpose or effect of something is to promote a product, it will most likely be captured. I say to the hon. Member for Windsor, “Worry not”: the ASA knows how the internet works, because it is dealing with it daily, and as we speak.

How does liability work? The offence will be charged on a case-by-case basis. In most cases, we expect that this will involve a company. The ASA is experienced in making decisions on tobacco restrictions at the moment, and the provision merely extends the powers and responsibilities that it is already undertaking with regard to a variety of other products. On social media influencers, it depends on how the ASA approaches the matter; if it decides that something is constituted as an advert, action can be taken. Nobody is above the law of the United Kingdom.

The hon. Member for Windsor asked why we are making changes to the law without consulting. To be clear, tobacco adverts are already banned under the Tobacco Advertising and Promotion Act 2002, and the provisions in part 6 of the Bill will simply maintain the existing ban on tobacco advertisements. We were elected with a mandate to carry out our manifesto commitments, one of which was to stop the advertising of vapes to children. We already know that the measures to restrict vape advertising are strongly supported: 74% of adults in Great Britain support banning the advertising and promotion of e-cigarettes at point of sale, at the till, in stores and as people enter shops, and only 6% are opposed.

Does aligning vapes with tobacco in this area contribute to misconceptions that vapes are just as harmful as tobacco? Although the approach towards vapes and towards tobacco will align in this area, our future regulations on other vape measures will be carefully considered so that there is a clear difference between these products. Given that vapes are less harmful than tobacco, we do not intend to treat them in exactly the same way as tobacco. To be clear, there is no more dangerous product that is legally sold in our shops than tobacco—a product that kills two thirds of its users—but we do not want to inadvertently addict a new generation to nicotine. That is the reason for the advertising measures.

Will the ban on the advertising of heated tobacco products increase the demand for traditional cigarettes? The Department’s opinion is that heated tobacco products are covered under the 2002 Act, which prohibits the advertisement and sponsorship of tobacco products. The new definition just ensures clarity on the scope of the legislation, as well as future-proofing policy. This is not a new ban; we believe that the existing tobacco advertising ban appertains to heated tobacco products in any case.

We very much want people to give up all forms of tobacco. That is why this Government have invested a further £70 million for smoking cessation services in the new financial year, and why I maintain that, although we are saying to tobacco companies, “This is as good as it gets,” we will move heaven and earth to shrink their customer base even further with appropriate smoking cessation. With that, I ask the shadow Minister to withdraw her amendment, and commend the clauses to the Committee.

[Dr Johnson]

The Minister knows that I believe strongly that we need to stop people smoking, because of its dangers, and that we need to stop children from taking up any form of nicotine, because we have heard how harmful nicotine is to them. He will also be aware of my argument—which I made in relation to the previous iteration of the Bill—that advertising, marketing and sponsorship should be included to reduce the appeal of the products to children. I support the clauses, but I was keen to debate how smoking cessation services will be able to discuss these products. The Minister has been reasonably, if not absolutely, clear on that, so I beg to ask leave to withdraw the amendment.

Amendment, by leave, withdrawn.

Clause 114 ordered to stand part of the Bill.

Clauses 115 to 119 ordered to stand part of the Bill.

Ordered, That further consideration be now adjourned. —(Taiwo Owatemi.)

Tobacco and Vapes Bill (Ninth sitting)

Andrew Gwynne Excerpts

Committee stage
Tuesday 21st January 2025 Public Bill Committees

[Jack Rankin]

I thank the hon. Member for providing that clarity. That is good to hear, but it is important to put on the record that we in this House should apply the same rules to ourselves as we apply to our constituents.

Again, as a non-lawyer, I ask the Minister for some clarification on the implications of the non-criminal liability of the Crown in clause 47(2) and how that sits alongside the reference to

“persons in the service of the Crown”

in subsection (4). What I am seeking is consistency between what applies in the real world and what applies to the Crown. Perhaps the Minister could say what that provision means in laymen’s terms, so that I can say to my constituents that what we are applying to them also applies to us.

I want to add to the point made by my hon. Friend the Member for Farnham and Bordon. If you will forgive me, Sir Roger, I will be a bit parochial to illustrate the point. I said earlier that the Crown is quite a nebulous concept for a legislator, and where it begins and ends is difficult to understand. It is often taken to mean the state more broadly, but I have another example, from my constituency. Windsor Great Park is Crown Estate—the arm’s length Government body that the House has been legislating on in the past weeks—but the castle itself is owned and managed by the royal household. In my casework and when dealing with stakeholders, I often find that different rules apply to the Crown Estate and the royal household. The royal household seems to have much more personal control from the monarch, whereas the Crown Estate is very much run by the trustees, effectively on behalf of the Treasury.

It would be good to understand what we mean when we talk about the Crown. It is clear from my hon. Friend the shadow Minister’s remarks that we are talking about the palaces, but it would be good to know whether the clause applies to all these different arms of the British state in some way, shape or form, or whether other provisions apply to them.

[The Parliamentary Under-Secretary of State for Health and Social Care (Andrew Gwynne)]

It is a pleasure to serve under your chairmanship, Sir Roger. I am grateful to hon. Members for their questions on these clauses, which are entirely technical and appertain to the treatment of the Crown in relation to the measures in the Bill. They follow a general Crown application, being broadly similar to, and mirroring pretty closely, the way other Acts of Parliament deal with the Crown. I am not sure whether the fact we have spent more than half an hour debating them shows Parliament at its best or at its niggliest, but we are having the debate none the less.

[Gregory Stafford]

I take the Minister’s point that the clauses are technical, but if we are not here to ensure that legislation is drafted correctly and appropriately, what are we here for?

--- Later in debate ---

[Andrew Gwynne]

We are here to ensure that the Bill gets on the statute book. I was under the impression—perhaps the misapprehension—that at least the two Opposition Front Benchers, the hon. Members for Farnham and Bordon and for Sleaford and North Hykeham, were supportive of the measures in the Bill. If so, we seem to have spent an extraordinary amount of time discussing matters that do not really affect the Bill, except in relation to the Crown.

[Dr Johnson]

Will the Minister give way?

[Andrew Gwynne]

Perhaps the hon. Lady will let me finish. The measures are standard practice for any Bill, but Members have put some questions to me, so I will reassure them about some of the issues they have raised. But before doing so, I will give way to the shadow Minister, who has had plenty of time to talk about this matter.

[Dr Johnson]

I thank the Minister for giving way. I want to echo the point made by my hon. Friend the Member for Farnham and Bordon that the purpose of line-by-line scrutiny is to do just that: to go through the Bill line by line. The Minister’s job might be to get things on the statute book for his Prime Minister and Cabinet and for the Government in which he serves, but surely he wishes to ensure that the Bill he is leading on is in the best possible condition. That is the purpose of the line-by-line scrutiny that we are in Committee to do.

[Andrew Gwynne]

I absolutely do with that. The point I am making is that we have just over another week to deal with these matters. If we get to the end of next week not having considered important chunks of the Bill because we have wasted time on silly little matters that appertain not only to the whole of this legislation, but to other legislation as well, and on fairly standard clauses relating to how legislation deals with the Crown, that will be on His Majesty’s loyal Opposition.

I will make progress and answer the points that were made. Why are clauses 47 and 137 necessary parts of the Bill? The presumption is that legislation does not apply to the Crown unless expressly stated as doing so. The clauses clarify that provisions in parts 1 and 6 of the Bill, and in the regulations made under them, bind the Crown. They ensure that all bodies and persons acting as public servants of the Crown are held to the same standards as businesses and private citizens in England and Wales. They ensure consistent application of the Bill across the public and private sectors.

Does the Bill bind Parliament? Yes, it does. Parliament was consulted and was content with clause 159, in particular, being included. We have already had the debate about snuff, and it will be up to the House authorities to determine the rules of the House. There is absolutely nothing to prevent there being a box at the entrance to the Chamber with the latest chief Doorkeeper’s name engraved on it—that tradition can remain for evermore—just as we have a Smoking Room, which we can no longer smoke in but which is still called the Smoking Room. That is tradition. I really do not know why Members are overthinking these matters.

Members asked why there are differences between Crown applications in the devolved Administrations. As we have already discussed, the Bill brings together legislation from across the four nations. I believe it is a triumph, because it shows the close working relationship between the Labour Government and the devolved Administrations, irrespective of the parties in power in Cardiff Bay, Holyrood and Belfast. Because health is a devolved matter, and because the Bill builds on legislation dating back nearly 100 years in some cases, there are some differences in the provisions for each nation.

Members asked why only some parts of the Bill apply to the Crown. The fact is that clauses 47 and 134 explicitly provide that parts 1 and 6, and any regulations made under them, apply to the Crown. Other measures in the Bill also apply to the Crown without the Bill’s explicitly stating so because those provisions amend existing legislation, and the Crown application reflects whether the underlying legislation applies to the Crown.

There is an established precedent that smoke-free places legislation does not apply to the Crown in England and Wales, and that it is the responsibility of the Department responsible for running the relevant part of the Crown Estate to determine what is appropriate. That is precisely what the House of Commons did when it determined that the smoking ban would apply to the royal Palace of Westminster. The same is true of all the measures in the Bill.

Members asked which parts of the Bill will apply to the Crown. Part 1 and regulations made under it apply to the Crown by virtue of clause 47.

The hon. Member for Sleaford and North Hykeham asked about Northern Ireland. Part 3 amends existing legislation in Northern Ireland, and it does not apply to the Crown. That is an existing precedent, which the Department of Health in Northern Ireland wishes to retain. Part 2 amends the existing legislation in Scotland and part 1 amends the legislation in England and Wales. That is why there is a different approach to different parts of the United Kingdom in respect of the Crown.

Members asked why we need clause 66, the technical clause relating to the Scottish Government. It is because it corrects an omission in the Tobacco and Primary Medical Services (Scotland) Act 2010, and it is being made at the request of the Scottish Government. It is a convention that in an Act of the Scottish Parliament those responsible for the enforcement of the legislation are explicitly identified as being able to make an application to the Court of Session for the purposes outlined in the clause. Scottish Ministers may take over enforcement under the 2010 Act, so it is appropriate that they are listed alongside local authorities, which is what clause 66 achieves. The clause inserts a provision into the 2010 Act, which is Scottish law. There are no impacts on the law in England, Wales or Northern Ireland. The clause is narrow and relates only to provisions in part 1 of the 2010 Act.

Members asked about overburdening the court. We are working the Ministry of Justice to ensure that the Bill does not introduce a significant burden. This is about regulatory change—and, look, most citizens are law abiding and will follow the law.

Question put, That the clause stand part of the Bill.

--- Later in debate ---

Clause 83 substitutes article 7 of the Health and Personal Social Services (Northern Ireland) Order 1978 with proposed new articles 7 and 7A, which replicate clauses 48 and 49 of this Bill. Clause 112 provides definitions for part 5. New definitions include “importer”, which is a person who imports a nicotine product into the UK in the course of business. This definition applies to part 5 on product and information requirements, which we have not come to yet. Clause 113 provides a definition of “nicotine product” to explain part 5, and clause 135 does the same for other definitions in part 6. Clause 132 expands the definition of “tobacco product” in section 1 of the Tobacco Advertising and Promotion Act 2002 to include those consumed in any other way, so that it is not just confined to those that are smoked, sniffed, chewed or sucked, but includes the other groups that we have talked about.

[Andrew Gwynne]

I thank the shadow Minister for the points she has raised. Definitions are needed to ensure that the legislation can be interpreted with an appropriate understanding of the technical terms, and we have opted to take a co-ordinated approach to definitions across the four nations, which will hopefully ensure clarity for the public, retailers and enforcers.

As we know, nicotine is a highly addictive drug, particularly for adolescents whose brains are still developing. As mentioned in the Bill, a nicotine product means any device, part of a device, or substance containing nicotine that is intended to deliver nicotine to the human body. There are currently no age of sale or advertising restrictions for products such as nicotine pouches—and, unlike vapes, there are no set nicotine limits. Nicotine strengths can vary from 2 mg per pouch to, in some cases, 150 mg or more. Like vapes, they can come in a variety of flavours and colourful packaging designed to appeal to children. The use of nicotine products such as nicotine pouches is increasing, particularly among young men. As we are committed to doing everything we can to protect children from becoming addicted to nicotine, it is only right to take action to control these products.

[Dr Johnson]

On the point about nicotine pouches, it is of concern that they may be the next way in which this industry seeks to make our young people addicted to nicotine. We have seen in places such as Sweden a plethora of these products, which are now expanding across the UK as well. I know the Minister will be looking at some proposals to restrict the amount of nicotine in the pouches. When he does so, will he consider not just how much nicotine is in them compared with a cigarette, but how much is absorbed into the body? The amount in a cigarette that is absorbed as a proportion is much lower than that of a nicotine pouch.

[Andrew Gwynne]

Those are important considerations for when we are developing the regulations, and I take precisely the same view as the shadow Minister. These things have to be part of that overall analysis and equation when we come to look carefully at the regulations.

The shadow Minister asked a number of questions. First, she asked whether a provisional driving licence would be applicable, and the simple answer is that it would. She also asked whether there is a loophole here with medicinal products, and whether children could be restricted from purchasing vaping substances for a future vape that may have medicinal approvals. Of course, it is important to point out to the Committee that to date no such vape exists. As per all licensed medicines, if one existed, it would be regulated by medicine regulations, which are subject to higher standards set by the MHRA.

The health advice is that nicotine replacement treatment, for example, is most effective when provided alongside expert advice. That is really important, and that is why we are putting money into smoking cessation services and why measures in the Bill will permit the distribution of free vapes by the NHS and public health authorities; we think that is entirely appropriate.

There is no age of sale restriction for nicotine replacement therapies. In extreme circumstances, for example, were there a MHRA-approved vaping device that met the criteria of a medical device, I suppose the vaping liquid could be prescribed to a child if that were appropriate. That is all hypothetical because there is not such a device approved by the MHRA; therefore, there is not the loophole the hon. Member for Sleaford and North Hykeham thinks there might be, although she is right to raise it.

[Dr Johnson]

To clarify the point about there being no device available, that had been my understanding as well, but Dr Laura Squire from the MHRA said in evidence to the Committee that in 2015 a vape had been approved for medical use, but had never been marketed. Has the licence for that product lapsed in some way so that it is no longer available?

[Andrew Gwynne]

I do not know, but I will ensure the Committee is informed by officials. My point is that it is not marketed. Therefore, there is no medical device on the UK market, and all that is currently hypothetical. We have to legislate for the future, which is why I said that nicotine replacement therapy is the most appropriate form of treatment for children. Were there a device at some stage in the future that was available for the NHS to use in a medical context—as opposed to swap to stop—then it would be appropriate for a doctor to be able to prescribe that should they wish to. However, that would be within a highly regulated medical setting, as opposed to just getting liquids from a vape shop.

[Dr Johnson]

Clauses 48 and 49 exempt the medicinal product and medical devices. I understand why the Minister has done that, but how is he going to ensure that the industry does not find ways of making the nicotine replacement products that are currently legal and used only for medical purposes lemonade, gummy bear or unicorn milk-flavoured, and therefore attractive to children? The Committee has heard repeatedly about the way the industry behaves.

[Andrew Gwynne]

We absolutely have thought about that, which is why the measures in the Bill and the powers it gives to Ministers across the jurisdictions of the United Kingdom enable regulations to be made to ensure that we always keep up with where the industry is going and—importantly—where the evidence is going. This is not just about where the industry might go; it may be that at some stage in the future there is new medical research showing that even the levels we are talking about lowering to have safety issues, and we will need to react to that.

That is why I will defend the way the Bill has been drafted, ensuring that Ministers will be able, at any stage in the future, to return to Parliament or the devolved legislatures to seek changes to secondary legislation to ensure that the measures are always relevant to the circumstances of the day.

Question put and agreed to.

Clause 48 accordingly ordered to stand part of the Bill.

Clause 49 ordered to stand part of the Bill.

[The Chair]

I apologise to the Committee; this is quite complex, even by my standards. Amendments 25 to 31 were debated under clause 1. The lead amendment, which was similar, was negatived by the Committee on a Division, and so I am not selecting them for a separate Division. That is in my gift.

Amendment proposed: 67, in clause 50, page 25, line 34, at end insert—

“(ba) in subsection (5), at end insert “, save if it is a first offence.”

(bb) after subsection (5) insert—

‘(5A) A person who has admitted guilt of a first offence under subsection (1) is liable to a fine not exceeding level 3 on the standard scale or a recorded police warning.’”—(Dr Johnson.)

This amendment prevents penalties for a first offence of selling tobacco products to person under 18 in Scotland being a fine not beyond level 3 and provides for a discretionary recorded police warning.

Question put, That the amendment be made.

--- Later in debate ---

Clause 53 will repeal section 7 of the Tobacco and Primary Medical Services (Scotland) Act, which enables the confiscation of tobacco products from children. I understand why the Minister is happy for the Scots to act as they wish, but confiscating such products is useful. We have talked about the proportionality of offences. If a constable were to see a child in the street with a vape or a cigarette, they could take those articles off them to prevent the child from using them. Clause 53 will remove that power and will to some extent weaken the law as it applies to smoking and vaping products. Will the Minister explain what rationale Ministers in Scotland have given him for wishing to weaken the law in that respect? Will he also explain why, conversely, he does not wish to strengthen it in England?

[Andrew Gwynne]

In answer to the shadow Minister, clause 52 will repeal the offence for someone under the age of 18 in Scotland of buying or attempting to buy a tobacco product or cigarette papers. It means that it will no longer be an offence for someone under the age of 18 to buy or attempt to buy those products in Scotland. That is because Scotland is the only part of the United Kingdom in which it is an offence for those under 18 to purchase tobacco products. The repeal will align the legal approach across the whole United Kingdom. It is being done after consultation and with the full consent of the Scottish Government. With the change to the age of sale, it was no longer deemed necessary to retain this provision, as the age-of-sale restrictions apply to the sale and not the purchase of tobacco products.

Clause 53 will repeal the power for constables in Scotland to confiscate tobacco products or cigarette papers from someone in a public place whom they suspect to be under 18. Both provisions were originally made in the Tobacco and Primary Medical Services (Scotland) Act 2010. Repealing them will ensure that legislation in Scotland is in line with legislation in England, Wales and Northern Ireland. With the change to the age of sale, it was no longer considered necessary to retain the provision, as age-of-sale restrictions apply to the sale and not the purchase of tobacco products. As we have already debated, that will ensure that we do not criminalise children.

Question put and agreed to.

Clause 52 accordingly ordered to stand part of the Bill.

Clause 53 ordered to stand part of the Bill.

Clause 54

Extension of tobacco legislation to herbal smoking products

Question proposed, That the clause stand part of the Bill.

[Dr Johnson]

Clause 54 will extend tobacco legislation to cover herbal smoking products, which are products made from plant material and intended for smoking that do not contain tobacco. It will amend section 4 of the Tobacco and Primary Medical Services (Scotland) Act, which governs the sale of tobacco products to individuals under 18, by inserting “herbal smoking product” after “tobacco product” in subsection (1). This will mean that the sale of herbal smoking products is subject to the same restrictions as tobacco products and is prohibited to persons under 18.

The clause will also amend section 4C of the 2010 Act, which deals with the sale of tobacco-related products by persons under 18, by adding “herbal smoking product” so that individuals under 18 are also prohibited from selling herbal smoking products. This is distinct from the ability to buy them, for which there will be a rolling age; it applies to the selling of these products.

The clause will also modify section 6 of the Act, which addresses the purchase of tobacco products on behalf of individuals under 18, otherwise known as proxy purchasing. It will amend subsection (1) by inserting “herbal smoking product” after “tobacco product”, making it illegal for anyone to purchase herbal smoking products on behalf of individuals under 18.

Finally, the clause will insert into section 35 a definition for herbal smoking products. This was covered in clause 48 and clause 1; clause 54 will add it to Scottish legislation. It specifies that a herbal smoking product is one that is made entirely or partially of vegetable matter and that is intended to be smoked, but that does not contain tobacco. Given our previous debate, these seem reasonable changes to make.

[Andrew Gwynne]

I will not detain the Committee on this question. As the shadow Minister says, these are reasonable changes to make and are in line with the clauses that we have just discussed.

Question put and agreed to.

Clause 54 accordingly ordered to stand part of the Bill.

Clauses 55 to 57 ordered to stand part of the Bill.

Clause 58

Possession of snus etc with intent to supply

Amendment proposed: 70, in clause 58, page 29, line 19, at end insert

“, save if it is a first offence.”—(Dr Johnson.)

See explanatory statement to Amendment 72.

Question put, That the amendment be made.

--- Later in debate ---

[Dr Johnson]

Clause 65 introduces schedule 9, which will amend the Tobacco and Primary Medical Services (Scotland) Act 2010 to broaden the scope of the retailer register and make related provisions to include herbal smoking products, vaping products and nicotine products, alongside tobacco. The amendments that it makes aim to regulate businesses that sell those products in a similar way to tobacco products.

Essentially, in schedule 9, the key changes are as follows. There will be an expansion of the register: section 10 of the 2010 Act will be amended to require the Scottish Ministers to maintain a register of businesses that are selling tobacco, herbal smoking products, vaping products and nicotine products. It will ensure that all those categories are subject to the same regulatory framework as respects the register.

There is clarification within the schedule of a “registrable business”, which is now defined to include any businesses dealing with tobacco, herbal smoking, vaping or nicotine products. The term is used throughout the Act, ensuring that all relevant businesses are captured under the regulations.

The amendments that schedule 9 will make to section 11 of the 2010 Act require applicants to specify which type of registrable business they intend to operate at each premises —essentially, which products they wish to sell. Can the Minister confirm that that means that some businesses could register to sell some products but not others under the Act? Perhaps they could sell tobacco products but not nicotine products, or vice versa. The registration process will be updated to reflect those additions.

Section 12 of the 2010 Act, which deals with certifications and notifications, will be amended to require certificates of registration to specify the type of product that a business sells. Additionally, under section 13, businesses must notify the Scottish Ministers of any changes, such as if they no longer desire to sell a specific type of registrable product. The Act’s provisions concerning banning orders, offences and public inspection of the register will be updated to reflect the inclusion of herbal smoking products, vaping products and nicotine products alongside tobacco products.

In addition, schedule 9 will add new definitions, including of “herbal smoking product business” and “nicotine product business”, ensuring clarity in the application of the law.

[Andrew Gwynne]

I welcome the shadow Minister’s comments. Of course, health is a devolved matter. Scotland has a long-established and functioning register of tobacco and nicotine vape product retailers. The Bill will expand Scotland’s registration scheme to include retailers selling herbal smoking products and nicotine products. The Scottish Government’s view is that introducing a licensing scheme at this time would put undue pressure on local authorities and the retail sector in Scotland. In line with the Scottish Government’s tobacco and vaping framework, the technical infrastructure of the register is being improved, which has been welcomed by stakeholders. Each of the nations of the United Kingdom is taking forward an approach that best suits its population.

--- Later in debate ---

[Dr Johnson]

Clause 84 is a short clause that extends the retail register provisions in Northern Ireland. It states:

“Schedule 10 amends the Tobacco Retailers Act (Northern Ireland) 2014 (c. 4 (N.I.)) to extend certain provisions about the registration of tobacco retailers so that they apply in relation to retailers of vaping products and nicotine products.”

Schedule 10 ensures that retailers selling tobacco products, herbal smoking products and cigarette papers are covered by the scheme.

[Andrew Gwynne]

As the shadow Minister says, the clause extends the existing registration scheme by expanding it to businesses that sell relevant products. The register will be expanded while the new licensing regulations are introduced, ensuring a stronger and consistent enforcement regime at all times.

Question put and agreed to.

Clause 84 accordingly ordered to stand part of the Bill.

Schedule 10 agreed to.

Clause 85 ordered to stand part of the Bill.

Schedules 11 to 13 agreed to.

Clauses 86 and 87 ordered to stand part of the Bill.

Schedule 14 and 15 agreed to.

Clause 88 ordered to stand part of the Bill.

Clause 89

Power of officer of Revenue and Customs to seize and detain snus etc

Question proposed, That the clause stand part of the Bill.

[Dr Johnson]

Clause 89 is such an important clause in that it forms a whole part of the Bill, part 4, by itself; whereas other parts contain multiple clauses, part 4 only contains clause 89. The clause deals with the power of a Revenue and Customs official to seize and detain snus, which the Bill defines as an oral tobacco product that

“is not intended to be inhaled or chewed”.

Hon. Members will remember that snus is a tobacco product that the Bill treats differently from all other tobacco products; there is a much heftier penalty for sale and a complete ban on manufacture. In line with the fact that it is dealt with differently from other tobacco products and that it will be illegal to manufacture and import, there needs to be provision for customs officials to deal with the snus if they find it.

Subsection (1) allows a Revenue and Customs officer to

“seize any relevant oral tobacco products that have been imported and detain them for no more than 48 hours.”

I presume that 48 hours is standard; the Minister may be able to expand on that. Any products seized and detained under this clause

“must be dealt with during their period of detention in such manner as the Commissioners for His Majesty’s Revenue and Customs may direct…For the purposes of calculating the 48-hour period mentioned…any period falling on a non-working day is to be disregarded.”

The Minister will be able to confirm, but I presume that is essentially saying that, if a product were seized on a Friday at 4.50 pm, they would get all of Saturday and Sunday and until late on the Tuesday to deal with the snus and would be able to seize it for that period.

The clause says that non-working days are Saturdays, Sundays and bank holidays; that is fairly straightforward. A relevant offence is an offence under clause 9 of the Bill in England and Wales, section 9C of the Tobacco and Primary Medical Services (Scotland) Act 2010, which is inserted by the Bill, and article 4G of the Health and Personal Social Services (Northern Ireland) Order 1978, which is also inserted by the Bill.

[Dr Johnson]

My hon. Friend is right to probe the Minister on those questions. It is important to understand why things are chosen. The Minister has sometimes referred to things being chosen because that is the way they were before, but the writing of new primary legislation offers a not-frequent opportunity to change things that may not be working very well. When items are seized at the moment, is the Minister’s advice from his civil servants that 48 hours is an adequate period of time in which to deal with all the paperwork that presumably needs to be done? Is it too long, and could it be shorter if it needed to be?

The commissioners for His Majesty’s Revenue and Customs are responsible for dealing with the relevant oral tobacco product during the period of detention, but that will not prevent the importation of snus for personal use. Can the Minister explain why that is the case?

[Andrew Gwynne]

It is not illegal to consume snus in the UK—I got told off for pronouncing that in Mancunian as “snuss” earlier, but each to their own—or to possess it for personal use. Clause 89 is that is intended to form part of a robust legislative framework in relation to oral tobacco products, and specifically helps to enforce other provisions of the Bill that prohibit possession with intent to supply in the course of business. It is common practice for customs officials to seize suspected illicit goods at the border. That will now also be applicable to snus products imported into the UK. The 48-hour period is standard practice, but after 48 hours the enforcement agency is able to decide on what action it wishes to take. I hope that answers the points raised by the shadow Minister and the hon. Member for Farnham and Bordon.

[Dr Johnson]

I want to understand how a customs official would make such a decision. The Minister has been clear that it is not illegal to possess snus—I hope I pronounced that properly—for personal use. However, it is an offence to manufacture it under clause 7, to sell it or offer it for sale under clause 8 or to possess it with intent to supply under clause 9. How would the Minister quantify an amount for personal use? Under ordinary circumstances, one could say—

Obesity: Food and Diet

Andrew Gwynne Excerpts

Monday 20th January 2025 Commons Chamber

[The Parliamentary Under-Secretary of State for Health and Social Care (Andrew Gwynne)]

I am grateful to the Backbench Business Committee for ensuring that this debate took place, and I am particularly grateful to my hon. Friend the Member for Stroud (Dr Opher) for securing it in the first place. I am also grateful to all Members for their valuable contributions. We have heard speeches from across the House, including from my hon. Friends the Members for Bolton South and Walkden (Yasmin Qureshi), for Chelsea and Fulham (Ben Coleman), for Ilford South (Jas Athwal), for Swindon North (Will Stone), for Liverpool West Derby (Ian Byrne), for Washington and Gateshead South (Mrs Hodgson), for Worthing West (Dr Cooper), for Southend East and Rochford (Mr Alaba), for Blackpool South (Chris Webb), for Bathgate and Linlithgow (Kirsteen Sullivan), for Dudley (Sonia Kumar), for Dartford (Jim Dickson), for Mid Cheshire (Andrew Cooper) and for Bury St Edmunds and Stowmarket (Peter Prinsley).

On the Opposition Benches, we heard from the right hon. Member for Wetherby and Easingwold (Sir Alec Shelbrooke), who I have to say looks so healthy as a consequence of the medication he is taking. I remember what he looked like before—he is a shadow of his former self. We also heard from the hon. Members for Newbury (Mr Dillon), for Chester South and Eddisbury (Aphra Brandreth), for Caerfyrddin (Ann Davies), for Honiton and Sidmouth (Richard Foord), for Lagan Valley (Sorcha Eastwood), for Strangford (Jim Shannon) and for Stratford-on-Avon (Manuela Perteghella), and then obviously from the Opposition spokespeople for the Liberal Democrats and the official Opposition.

The United Kingdom has an obesity crisis. It poses serious challenges to our health, adds preventable pressure on the NHS, and restricts our economic productivity. I am reassured that none of us in the Chamber today underestimates the scale or importance of the task ahead, and we all recognise the need for action. I am proud that this Labour Government have already acted on manifesto commitments in several key areas, as I will outline, but I am also aware that much more needs to be done.

Over two thirds of adults are living with excess weight, and around 36% of children are living with obesity or are overweight by the time they leave primary school. That is appalling, but while it is shocking by itself, that average hides the deep inequalities we see in obesity. Children living in poorer areas are more than twice as likely to be living with obesity than those living in the least deprived areas. That has a huge impact on our lives, increasing the risk of many serious diseases—as we have heard—as well as exacerbating mental health issues and reducing the years that we and our loved ones can expect to live in good health. Almost 22% of all working-age people are economically inactive, and much of that is due to long-term health conditions caused or exacerbated by obesity. The cost of obesity-related conditions to the NHS now stands at £11.4 billion a year, and the cost to wider society is a staggering £74 billion every year.

I am so proud that we are committed to raising the healthiest generation of children ever. That means going further on prevention and tackling the drivers of obesity. Over recent decades in the UK, food and drink that is calorie dense, nutrient poor and less healthy has become cheaper. It is vital that we ensure our policies continue to drive companies to make food and drink healthier. That is why this Government took action to uprate the soft drinks industry levy in the October Budget. That levy has already taken thousands of tonnes of sugar out of the drinks we consume every day, and I give credit to George Osborne, the Conservative Chancellor in the coalition Government, who introduced that measure. Uprating the levy is a key part of keeping it effective and continuing to drive reformulation towards healthier products.

However, this is not just about what is in our food and drinks; less healthy foods are more heavily promoted, marketed and advertised than ever before. One third of the food industry’s advertising budget is spent on marketing confectionery, snacks, desserts and soft drinks, while only around 1% of that budget is spent on marketing fruit and vegetables. It is therefore not a surprise that our children want to eat those products. One study estimated that 6.4% of UK childhood obesity is attributable to junk food TV advertising. That is why this Government have already met our manifesto commitment to lay the secondary legislation required to ensure the ban on junk food ads targeting our kids comes in from October this year. This includes a 9 pm TV watershed for the advertising of less healthy food and drink products, and a restriction on paid-for online advertising of all these products.

[Jim Shannon]

The Minister is giving a very comprehensive response, and it is much appreciated. One of the things I asked for in my speech—I know he will do this, but I think we could probably do it better—is to look at initiatives in each of the regions of Scotland, Northern Ireland or Wales that could complement the policy driven from here. Is it the Minister’s intention to do that with the regional Administrations?

[Andrew Gwynne]

The advertising regulations of course cover the whole of the United Kingdom, but this Labour Government have a good working relationship with the devolved Governments in Northern Ireland, Scotland and Wales. We have the intergovernmental ministerial meetings, and we have been liaising closely on a whole range of public health measures, including the Tobacco and Vapes Bill, directly with ministerial counterparts in the devolved Governments. I want that relationship to deepen and mature because that is good governance across the whole United Kingdom.

We know that our chances of accessing healthy food depends on where people live. Children living in less affluent areas see five times more fast-food outlets on their high streets. That is why it is so important that strengthened the new national planning policy framework. Local authorities now have clearer powers to block fast-food outlets near schools, and also where children and young people congregate, to stop the relentless targeting of children and young people by the fast-food industry. Making the healthier choice the easier choice is a major part of achieving our shift to prevention. We will continue to look at ways to support people to make and sustain changes in their diet in line with the Government’s “Eatwell Guide”.

This may be a good point at which to clarify our position on ultra-processed foods. There are concerning associations between ultra-processed foods and negative health outcomes, including obesity. However, where the evidence is not yet clear is whether the negative health outcomes are due to processing or to these products tending to be high in calories, sugar, saturated fat and salt. I want to reassure hon. Members across the House that many ultra-processed foods are already captured by the existing healthy eating advice, policy actions and regulations relating to HFSS foods. Our scientific advisory committee on nutrition continues to monitor the evidence on ultra-processed foods, and we will commission further research where needed.

In my last few minutes, I will turn to a number of the issues that have been raised. First, just to reassure the shadow Minister, porridge oats will not be banned. The majority of porridge, muesli and granola products will not be affected by the restrictions, but some less healthy versions with added sugar, chocolate or syrup could be affected. To be in scope, products must fall within one of the categories of food and drink set out in the schedule to the advertising regulations and be defined as less healthy by the 2004-05 nutrient profiling model. For example, categories include but are not limited to soft drinks with added sugar, savoury snacks such as crisps, breakfast cereals, confectionery, ice cream and pizza. Despite recent media reports, the majority of porridge products will not be affected.

The right hon. Member for Wetherby and Easingwold made a really important point about stigma, and he is absolutely right that we really have to tackle stigma. Our genetics and our will power have not changed in the last 50 years. What has changed is the food environment and that we are bombarded with marketing for unhealthy foods. We already know that the issue is even worse in some of the poorer communities.

Finally, my hon. Friend the Member for Chelsea and Fulham and the hon. Member for Caerfyrddin mentioned accessibility to healthier affordable food. No child should live in poverty; that is why our ministerial taskforce is exploring all levers available across Government to give children the best start in life. We will tackle food insecurity by rolling out free breakfast clubs in every primary school and continuing to provide free healthy food during the holidays for children who receive free school meals. It is really important that we continue with that.

There is no silver bullet for obesity. This debate has shown that obesity is not just about health; it is about food, tax, education, business, employment, advertising and more. It is both a national challenge and a challenge within local communities. Our health mission is focused on shifting towards a more preventive approach which will benefit this agenda. In addition the Department for Environment, Food and Rural Affairs has announced an ambitious new cross-Government food strategy to work with the food industry to deliver on our goals for food security, health, affordability and the environment.

Obesity is a hugely complex challenge, but tackling it is a key part of achieving the change needed in this country. This Government are committed to taking effective action and I look forward to updating Members on what we do next.

Tobacco and Vapes Bill (Seventh sitting)

Andrew Gwynne Excerpts

Committee stage
Thursday 16th January 2025 Public Bill Committees

[Dr Caroline Johnson (Sleaford and North Hykeham) (Con)]

Clause 15 makes it an offence to give away or discount any vape product. That is important because discounts encourage us to buy more things. That is what they are there for; it is what promotions are for. They encourage us to buy things that we did not want or need. We do not want people to consume excessive quantities of vapes that they do not want to have, but that does happen. A cursory glance on the internet shows that numerous websites are advertising vape discount codes and vouchers offering 10% or 15% discounts on vapes, as well as giftcards that are readily available for online purchase. The clause therefore replaces section 9 of the Tobacco Advertising and Promotion Act 2002 and extends its scope, as there are currently no restrictions on businesses freely distributing nicotine and non-nicotine vaping products, cigarette papers and herbal smoking products.

In 2023 the former Prime Minister, my right hon. Friend the Member for Richmond and Northallerton (Rishi Sunak), created an illicit vapes enforcement squad, backed by £3 million. It was designed to close the legal loophole that allowed the vaping industry to provide free samples of vapes to be distributed regardless of consumer age. That was patently unacceptable, and I welcome the action that the previous Government took on the issue. I point out that giving away vapes was pretty common. In fact, my own parliamentary staffer went to a promotional event on vaping held in Parliament itself, in this very House, and was given free samples of Vuse vapes. I have been made aware by staffers that similar events take place outside Parliament, so I think that this is a useful clause and I will support it.

[The Parliamentary Under-Secretary of State for Health and Social Care (Andrew Gwynne)]

It is a pleasure to serve under your chairmanship, Sir Roger. May I start by not only thanking the shadow Minister for her support, but congratulating my hon. Friend the Member for Dartford on his birthday? [Hon. Members: “Hear, hear!”] It is a real pleasure that we are able to provide him with a full day’s entertainment—better than Netflix.

[Jim Dickson (Dartford) (Lab)]

I thank the Minister very much for his birthday felicitations. There is nowhere I would rather be than here.

[The Chair]

I only hope that is not open to challenge.

[Andrew Gwynne]

I was just about to say, Sir Roger, that might be one thing that we have to divide on later. I wish my hon. Friend the Member for Dartford all the best for today and hope that he gets home in reasonable time to enjoy with friends and family what is left of his birthday.

I thank hon. Members for their speeches on these clauses today and earlier this week. The Government have two objectives on vaping. The first is to tackle youth vaping. Too many children are vaping and vapes are attractive and accessible to them. The Bill will bring about definitive and positive change to prevent future generations from becoming hooked on nicotine. The second objective is to support adult smokers to access vapes to help them to quit smoking. As the chief medical officer says:

“If you smoke, vaping is safer; if you don’t smoke, don’t vape; and the marketing of vapes to children is utterly abhorrent.”––[Official Report, Tobacco and Vapes Public Bill Committee, 7 January 2025; c. 11, Q8.]

I concur with that entirely.

In support of those aims, the clauses do not apply to licensed medicines and there is a defence available when any free vaping or nicotine product is given out in accordance with arrangements made by a public health authority or a public authority. That means that smoking cessation services will be able to continue to support adult smokers to quit smoking, for example by providing free smoking cessation quit aids where appropriate. That includes our national swap to stop programme that continues to help smokers move from cigarettes to vapes.

I also stress that we will continue to work with the Medicines and Healthcare products Regulatory Agency to support applications from industry for vapes as a licensed medicine. As Dr Laura Squire, the MHRA chief healthcare quality and access officer, stated in the evidence session, there may be progress in this area. I hope that that assures hon. Members that we continue to take a balanced approach to vaping, both through the measures in the Bill and our wider work on tobacco control.

More generally, the clauses make it an offence to give away any tobacco, herbal smoking, vaping or nicotine product as well as cigarette papers if the purpose or effect is to promote any tobacco, herbal smoking, smoking-related, vaping or nicotine product to a member of the public of any age—for England and Wales, in clause 15, for Scotland, in clause 62, and for Northern Ireland, in clause 80. The maximum penalty for the offence will be imprisonment for up to two years, a fine, or both.

The clause also extends to coupons and vouchers and to selling a product at a substantial discount. These measures mean that disreputable actors cannot bypass the restriction by offering a free voucher for a product instead of a free product. The clause also covers products that promote any of the aforementioned products—for example, t-shirts with vape company branding to promote vapes cannot be freely given away. On discounts, we are only prohibiting substantial discounts, so we can make sure that businesses cannot heavily discount products to the point at which the price is no longer relevant. Businesses can still discount products if they choose to. Clause 62 also includes a power for Scottish Ministers to create additional defences.

It should never have been the case that addictive nicotine and vaping products could be legally handed out for free. This is one of the many avenues by which industry is addicting our children. It is for these reasons I commend the clauses to the Committee.

Question put and agreed to.

Clause 15 accordingly ordered to stand part of the Bill.

Clause 16

Prohibition of retail sales of tobacco products etc in England without a licence

Question proposed, That the clause stand part of the Bill.

[The Chair]

With this it will be convenient to discuss the following:

Schedule 1.

Clauses 17 and 18 stand part.

Schedule 2.

Clause 19 stand part.

Schedule 3.

Clauses 20 and 21 stand part.

Schedule 4.

Clause 22 stand part.

Clause 85 stand part.

Schedules 11 to 13.

--- Later in debate ---

[Sarah Bool]

My hon. Friend makes a valid point. We do not want the introduction of this legislation to lead to any overburdening. We do not want the smaller convenience stores that are trying to operate to be challenged and put out of business. We want this to be a very practical measure so I agree that would be something to look into. I wonder whether the Minister might offer any further thoughts on that.

[Andrew Gwynne]

I thank Members for their contributions.

Clauses 16 to 22, clause 85, and schedules 1 to 4 and 11 to 13 establish powers for Ministers in England, Wales and Northern Ireland to introduce a licensing scheme for the retail sale of tobacco, vaping products, nicotine products, cigarette papers and herbal smoking products. There is currently no requirement for a business to obtain a licence to sell these products, which is a major gap in enforcement. This gap is hard to defend since the sale of products such as alcohol does require a licence, while tobacco—the single biggest preventable cause of death, disability and ill health—does not. Vaping and nicotine products also carry, as we have heard, a significant risk of harm and addiction.

Introducing a licensing scheme will strengthen enforcement of the law, acting as a deterrent to rogue retailers who breach sales regulations, supporting legitimate businesses and ultimately supporting public health outcomes. Retail licensing is a highly popular intervention, as the shadow Minister helpfully pointed out, because the polling shows that 81% of retailers and 83% of the public are supportive of tobacco retail licensing, and it is one of the most popular tobacco interventions surveyed.

Clause 16 establishes that an individual in England is required to hold a personal licence in order to sell tobacco, vaping products or nicotine products, expose those products for sale, and possess products for sale. The clause also establishes that a person must have a premises licence for any premises in England used for the storage, exposure or supply of a relevant product to a retail customer.

The clause provides for a discretionary power for the Secretary of State to make exceptions by regulations to the requirements for a personal or premises licence. This will enable regulations to appropriately account for all possible types of retail. The Secretary of State in England must, by regulations, make provisions for how licences are to be granted and must conduct a consultation before regulations are introduced. The scheme will be commenced by regulations.

I hope that in part answers the question posed by the hon. Member for Farnham and Bordon, because we want to ensure that the licensing regime is fit for purpose not just for bricks and mortar businesses, but for online business.

[Dr Caroline Johnson]

Will the Minister address under which part of the legislation regulations will be made in Scotland?

[Andrew Gwynne]

I will come to Scotland in due course.

Schedule 1 establishes the framework for the regulations. It establishes that the licensing authority will be the local authority, and defines the relevant types of local authority that regulations could establish as the licensing authority. In answer to the shadow Minister’s question, given that there is likely to be local government reorganisation in the future, it will be, and will remain, the responsibility of the outgoing local authority that is the licensing authority to continue the licensing function up to the date that the new local authority comes in, out of a shadow form.

The usual practice in local government reorganisation is that a shadow local authority is in place for a year in advance. It sorts out restructuring and necessary background work, with local members who were elected to the shadow authority becoming the members of the new local authority on the commencement date. That was true of the Local Government Acts in 1972 and 1996, and it has been true of local government reorganisations since. I have no reason to believe it will not be true of the next set of local government reorganisations. For a period of time, the outgoing local authority will be the licensing authority because it is the local authority until the date that it moves to new arrangements. From day one of the new arrangements, the new authority will be the licensing authority.

[Dr Johnson]

Some areas have a unitary authority, some have a unitary authority and a mayor, and some have restricted county councils. As local reorganisation occurs, how will the tier of local authority that has the competency and duties under this legislation be defined?

--- Later in debate ---

[Andrew Gwynne]

Where we know an area is moving from a two-tier to a unitary authority, the clue is in the name: the unitary authority will be the licensing authority because there will be only one local authority covering that area.

[Gregory Stafford]

I am sure the Minister has much greater understanding of his own Government’s policy, but my understanding is that there will be some devolution of powers to parish and town councils. Will they potentially become the licensing authority when there is a downward devolution of power?

[Andrew Gwynne]

No. The local authority, not the parish council, would be and will remain the licensing authority, as is the case at the present time. Notwithstanding that there may be a quasi-additional tier in the form of a mayor and a combined authority, where areas move from a two-tier to a unitary authority, it will be the local authority that is the licensing authority. That is what happens in my constituency in Greater Manchester, where we have effectively had unitary authorities since the metropolitan county council was abolished in 1986. Tameside metropolitan borough council and Manchester city council are both unitary authorities. They are both the licensing authorities for their respective parts of my constituency, even though we have a Greater Manchester combined authority and a Great Manchester metro mayor. I hope that clarifies the issue.

Schedule 1 also establishes that regulations may make provisions regarding the granting, duration, renewal and revocation of licences, and enables the licensing authority to charge a fee for the granting of a licence. In response to the point raised by the hon. Member for Windsor, the fee structure may be set at a level that takes into account administration and enforcement costs. The local authority will be able to use the fee to help cover the cost of granting licences and enforcing the scheme. That is the closest I can get: we intend it to be cost-neutral for the purpose of operating the scheme.

Schedule 1 establishes that regulations can place conditions on the licence. Retailers that breach those conditions will be subject to civil financial penalties. Regulations may make provision for licensing authorities to publish information about licences, such as the addresses of licensed retailers, and, to maintain fairness, regulations must include an appeals route, so that retailers can, for example, appeal decisions on the granting of a licence. Finally, regulations may require that a licensing authority must consider guidance published by the Secretary of State to support the smooth implementation of the scheme.

Clause 19 and schedule 3 establish the same power to introduce a licensing scheme in Wales, with the same framework for the regulations. The schedule establishes the licensing authority in Wales to be the council of the county or county borough. Clause 85 achieves the same in Northern Ireland by inserting a new clause into the Tobacco Retailers Act (Northern Ireland) 2014, while schedule 11 establishes the same framework. In Northern Ireland, a council will be the licensing authority.

Clause 17 creates offences in relation to the licensing scheme in England. It makes it an offence to sell, expose for sale, or possess for the purpose of sale any relevant products without, or not in accordance with, a personal licence. The clause also makes it an offence to use a premises in England for the storage of relevant product for the purpose of retail sale, the exposure for sale, or the supply of any relevant product to a retail customer without, or not in accordance with, a premises licence, and knowingly to provide materially false or misleading information in a licence application.

Anyone found to be committing a licensing offence may be issued with an unlimited fine on conviction. As an alternative to prosecution, trading standards may issue a £2,500 fixed penalty notice, which is an on-the-spot fine. Regulations can confer on courts a discretionary power to suspend or revoke a licence on conviction. The court may order relevant product to be forfeited and destroyed, to prevent a business from continuing to sell or unlawfully selling product.

Clause 20 establishes the same licensing offences in Wales, and clause 85 establishes the same licensing offences in Northern Ireland. In Northern Ireland, district councils will enforce the licensing scheme. People convicted of a licensing offence face a fine of up to £5,000. As an alternative to prosecution, councils in Northern Ireland can issue a fixed penalty notice, the value for which will be determined in regulations.

Clause 18 creates civil financial penalties for breaches of licence conditions in England, to ensure that licensed retailers continue to follow the rules. Breaching conditions is a civil matter, not dealt with by the courts. The value of the civil financial penalty cannot exceed £2,500. The clause also provides a limited and specific power to update that value to account for inflation, to ensure that the value remains relevant. A civil penalty cannot be issued if the breach of the licence condition already constitutes a licensing offence. That is to ensure that someone cannot be subject to double punishment for the same licence breach.

[Dr Johnson]

The power to increase the fine is in line with inflation, but if evidence over time showed the Minister that the fine was not adequate to deter the offence from taking place, the Government might wish to raise it by more than inflation, to provide a greater deterrent. Would it be wise to make the power more flexible?

[Andrew Gwynne]

As I have said during previous outings in the course of this Committee, the Bill merely rolls over the existing fines. We would need to do a much more complex piece of work to uprate the fines beyond the current values, plus inflation. That is not what the Bill seeks to do; we do not want to overcomplicate it.